 
           Official Title:   
A Randomized, Double- Blind, Placebo- Controlled, Phase 2 Dose 
Finding Study of ISIS 703802 (AKCEA -ANGPTL3 -LRx) Administered 
Subcutaneously to Subjects with Hypertriglyceridemia, Type 2 
Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease 
(NAFLD)  
Study ID: [REMOVED] 
Document Dates:  
Protocol Amendment 3 – 21 March 2019  
 
 
     
 
Sponsor:  
Akcea Therapeutics , Inc.  
[ADDRESS_907216], 9th Floor 
[LOCATION_011], MA  [ZIP_CODE] Collaborator: 
Ionis Pharmaceuticals, Inc.  
[ADDRESS_907217] 
Carlsbad, CA  [ZIP_CODE] 
 
 
ISIS 703802- CS2 
 
 
A Randomized, Double- Blind, Placebo -Controlled, Phase 2 Dose 
Finding Study of ISIS 703802 (AKCEA- ANGPTL3 -LRx) Administered 
Subcutaneously to Subjects with Hypertriglyceridemia, Type 2 Diabetes 
Mellitus (T2DM), and No nalcoholic Fatty Liver Disease (NAFLD)  
 
Protocol Amendment 3– 21 March  2019 
 
 

ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
3 ISIS 703802- CS2 
Protocol Number ISIS 703802-CS2  
Protocol Amendment 3 
Clinical Phase:  2 
A Randomized, Double- Blind, Placebo -Controlled, Phase 2 Dose 
Finding Study of ISIS 703802 (AKCEA- ANGPTL3 -LRx) Administered 
Subcutaneously to Subjects with Hypertriglyceridemia, Type 2 Diabetes 
Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)  
Trial Sponsor: Akcea Therapeutics , Inc.  
[ADDRESS_907218]:   
 - Akcea Therapeutics , 
Inc. 
[ADDRESS_907219], 9th Floor 
[LOCATION_011], MA [ZIP_CODE] 
 Phone:  
E-mail:  
Sponsor Medical Monitor:  MD 
 - A
kcea 
Therapeutics , Inc.  
[ADDRESS_907220], 9th Floor 
[LOCATION_011], MA  [ZIP_CODE] 
Phone:  
Mobile:  
E-mail:  
D
ate: [ADDRESS_907221] of the clinical investigation without the prior written consent of Ionis 
Pharmaceuticals, Inc.  and Akcea Therapeutics , Inc.
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
5 Protocol Signature [CONTACT_10669]:  ISIS 703802- CS2  
Protocol Title:  A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding 
Study of ISIS 703802 ( AKCEA- ANGPTL3 -LRx) Administered 
Subcutaneously to Subjects with Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD) 
Amendment:  Protocol Amendment 3 
Date:    [ADDRESS_907222] read and understand the attached clinical protocol, entitled A 
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (ISIS 703802) Administered Subcutaneously to Subjects with Hypertriglyceridemia, Type 2 Diabetes Mellitus ( T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)  dated [ADDRESS_907223] the study as described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline on 
Good Clinical Practice (E6 R2) and with the moral, ethical and scientific principles governing 
clinical research as set out in the Declaration of Helsinki (Version 2013). 
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Ionis Pharmaceuticals, Inc. , and Akcea Therapeutics, Inc.   
 
   
Investigator’s Signature  
   
[CONTACT_10670]’s Name (please print)   Date (DD Month YYYY)  
 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
6 TABLE OF CONTENTS  
 Page  
PROTOCOL SYNOPSIS  ........................................................................................................... 12  
STUDY DESIGN AND TREATMENT SCHEMA  .................................................................. 19  
STUDY GLOSSARY .................................................................................................................. 20  
1.  OBJECTIVES  ................................................................................................................. 25  
1.1 Primary Objective(s)  ......................................................................................................25  
1.2 Secondary Obj ective(s)  ..................................................................................................25  
2. BACKGROUND AND RATIO NALE  .......................................................................... 25  
2.1 Overview of Disease  ......................................................................................................25  
2.2 Therapeutic Rationale  ....................................................................................................26  
2.3 ISIS 703802 ...................................................................................................................27  
2.3.1  Mechanism of Action  .............................................................................................27  
2.3.2  Chemistry  ...............................................................................................................27  
2.3.3  Preclinical Experience  ............................................................................................28  
[IP_ADDRESS]  Preclinical Pharmacology  ................................................................................28  
[IP_ADDRESS]  Preclinical Toxicology  .....................................................................................29  
2.3.4  Clinical Experience ................................................................................................30  
[IP_ADDRESS]  ISIS 563580- CS1 Phase 1 SAD/MAD ............................................................31  
2.4 Rationale for Dose and Schedule of Administration .....................................................31  
2.5 Benefit -Risk Assessment  ...............................................................................................32  
2.5.1  Benefit Assessment  ................................................................................................32  
2.5.2  Risk Assessment  .....................................................................................................32  
2.5.3  Overall Assessment of Benefit: Risk  ......................................................................[ADDRESS_907224]- Treatment Period  ............................................................................................41  
6.2 Study/Laboratory Assessments  ......................................................................................41  
6.2.1  Physical Exams and Vital Signs  .............................................................................43  
6.2.2  Electrocardiography  ...............................................................................................43  
6.2.3  PK Sampling  ...........................................................................................................43  
6.3 Restriction on the Lifestyle of Subjects  .........................................................................43  
6.3.1  Contraception Requirements ..................................................................................43  
6.3.2  Other Requirements  ................................................................................................44  
7. STUDY DRUG  ................................................................................................................ 44  
7.1 Study Drug Description  .................................................................................................44  
7.1.1  ISIS 703802 (ISIS  703802) ....................................................................................[ADDRESS_907225] Results ....................................................54  
8.6.3  Stoppi[INVESTIGATOR_10424] ...............................................................54  
8.6.4  Stoppi[INVESTIGATOR_81715] .........................................57  
8.7 Adjustment of Dose and/or Treatment Schedule ...........................................................57  
8.8 Discontinuation of Study Drug/Treatment ....................................................................[ADDRESS_907226]-
Treatment Follow -up Period ..................................................................................58  
8.9 Withdrawal of Subjects from the Study .........................................................................58  
8.10  Concomitant Therapy and Procedures ...........................................................................58  
8.10.1  Concomitant Therapy  .............................................................................................59  
8.10.2  Concomitant Procedures .........................................................................................59  
8.11  Treatment Compliance  ...................................................................................................59  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ...................... 60  
9.1 Sponsor Review of Safety Information .........................................................................60  
9.2 Regulatory Requirements  ..............................................................................................60  
9.3 Definitions  .....................................................................................................................60  
9.3.1  Adverse Event  ........................................................................................................60  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................61  
9.3.3  Serious Adverse Event (SAE) ................................................................................61  
9.4 Monitoring and Recording of Adverse Events ..............................................................61  
9.4.1  Serious A dverse Events  ..........................................................................................61  
9.4.2  Non-Serious Adverse Events ..................................................................................62  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................62  
[IP_ADDRESS]  Relationship to the Study Drug ........................................................................62  
[IP_ADDRESS]  Severity  ............................................................................................................63  
[IP_ADDRESS]  Action Taken with Study Drug ........................................................................63  
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................................................63  
[IP_ADDRESS]  Outcome of the Adverse Event ........................................................................63  
9.5 Procedures for Handling Special Situations ..................................................................64  
9.5.1  Abnormalities of Laboratory Tests .........................................................................64  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............64  
9.5.3  Dosing Errors .........................................................................................................65  
9.5.4  Contraception and Pregnancy .................................................................................65  
10. STATISTICAL CONSIDERATIONS  .......................................................................... 66  
10.1  Study Endpoints, Subsets, and Covariates .....................................................................66  
10.1.1  Primary Endpoint ...................................................................................................66  
10.1.2  Secondary Endpoints ..............................................................................................66  
   
10.2  Sample Size Considerations ...........................................................................................67  
10.3  Populations .....................................................................................................................67  
10.4  Definition of Baseline  ....................................................................................................67  
10.5  Interim Analysis  .............................................................................................................67  
10.6  Planned Methods of Analysis ........................................................................................68  
10.6.1  Demographic and Baseline Characteristics  ............................................................68  
10.6.2  Safety Analysis  .......................................................................................................68  

ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
9 [IP_ADDRESS] Adverse Events ........................................................................................................68  
[IP_ADDRESS] Clinical Laboratory Data  ..........................................................................................68  
[IP_ADDRESS] Vital Signs and Examinations ..................................................................................68  
10.6.3  Efficacy Analysis  ...................................................................................................69  
 
10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................70  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  ............................................. [ADDRESS_907227] of the Study .........................................................................................71  
11.3  Independent  Ethics Com mittee/Institutional Review Board  .........................................[ADDRESS_907228] of Laboratory Analytes  .............................................................................85  
Appendix C  PK Sampling Schedule ....................................................................................87  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities......90  
Appendix E  Additional Laboratory Tests for Patients with Platelet Count <100,000/mm3 94 
 
TABLE OF TABLES  
Page  
Table 1  Study Drug Characteristics  ....................................................................................45  
Table 2  Study Drug Dosing Information  ............................................................................46  
Table 3  Actions in Subjects with Low Platelet Count  ........................................................56  
 
TABLE OF FIGURES  
Page  
Figure 1  Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  (MOE-
Gapmer).  The sequence of ISIS 703802 is shown. ...............................................28  
  

ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
10  
PROTOCOL AMENDMENT  
Protocol Num ber:  ISIS 703802- CS2 
Protocol Title:  A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study 
of ISIS 703802 ( AKCEA- ANGPTL3 -LRx) Administered Subcutaneously (SC) to 
Subjects with Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and 
Nonalcoholic Fatty Liver Disease (NAFLD)  
Amendment Number:  Protocol Amendment 3  
Amendment Date:  [ADDRESS_907229] been made.  
Minor changes (not included in the list of changes below) have been made throughout the 
protocol to correct errors and/or to improve the overall clarity of the original protocol but these changes do not impact subject safety, exposure, or the overall study design.  
The following table provides a summary list of major changes to the original protocol: 
Protocol Section  Description of Change  Rationale  
Title Pages  Update the Sponsor Approval and 
Sponsor
 Medical Monitor to  
 MD
. Change in Medical Monitor for the 
study  
Throughout  (including Synopsis)  Revise sample size for study  to 96 
randomized. The new per Cohort 
sample size is 32 randomized. This 
results in 24 patients receiving 
active drug and 8 pati ents receiving 
placebo.  Sponsor decision to revise sample 
size in order to accelerate further development for populations with serious hepatic steatosis. With the changes in sample size, the study 
remains adequately powered to 
provide the desired information on the 
primary objective and the key secondary objectives relevant to this 
population.  
Appendix A Schedule of 
Procedures – Weekly Dosing 
(Cohort A)  Updated Cohort A Appendix A Footer H text to read: “During follow -
up period, hematology sampling for platelet values are taken every 14 days (+/ - 2 days) for [ADDRESS_907230] dose of Study Drug, then at Week 8 and Week 13 Follow -up 
visits. ” The intent of Cohort A Schedule of Procedures Footer H is to clarify that 
hematology samples for platelet values should continue to be taken every 14 days (+/ - 2 days) after dosing 
stops. During the Treatment Period, Hematology samples are being drawn every two weeks starting at Week 1 and continuing through W27/ ET. It is 
important to note that even though Week [ADDRESS_907231] dose of IP is actually given at Week 26 for Cohort A. Therefore, bi-weekly hematology 
testing for platelet values should 
continue after dosing stops and taken  

ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
11 Protocol Section  Description of Change  Rationale  
at the following visits: Follow -up Week 
2; which is actually [ADDRESS_907232] 
dose), Follow -up Week 4; which is 
actually [ADDRESS_907233] dose), then at Follow -up Week 8 and Follow -up 
Week 13.  
Appendix A Schedule of Procedures – Every 4 -Week 
Dosing (Co horts B & C)  Updated Cohorts B & C Appendix A Footer H text to read: “ Cohorts B & 
C Footer H: During the follow -up 
period, hematology sampling for platelet values should continue to be 
taken every 14 days (+/ - 2 days) for 
6 weeks after Week 27/EOT, then at  
Week 4, Week 8 and Week 13 
Follow -up visits ” To clarify the language used in Footer H of Appendix A Schedule of Procedures. As the Follow -Up Visits 
are already defined in the table, Footer H served as an aid to help explain the 
timing of the hematology samples 
when transitioning from Treatment Period to Follow -up period.  
Section 4.[ADDRESS_907234] complets the treatment 
period.  To provide more specific informat ion 
on when the Sponsor will become 
unblinded.  
8.5.2 Safety Monitoring For Renal 
Function  The following Lab alerts for 
abnormal renal tests were updated:  
• UACR > 165 mg/g  
• UPCR > 325 mg/g  
• New onset hematuria defined as ≥ 5 RBC/hpf (except for 
menstruating females)  
• Abnormal test results should now be repeated.  
• Supplemental renal tests should 
now be obtained within 7 days, 
and additional laboratory studies may be performed to identify if other potential 
etiologies may be ca sual factor  
• The 24-hour urine sample, urine albumin, and urine protein were 
removed from the supplemental rental tests.  To align the renal monitoring criteria in 
this study with th e criteria used in 
clinical studies of other anti- sense 
oligonucleotides conducted by [CONTACT_429]  
8.6.[ADDRESS_907235] Results  The following updates were made to 
8.6.2:  
• 24-hour urine sample removed  
• eGFR criteria updated to: decrease of > 25% from 
baseline 
• Added criteria: 
o UACR > 165 mg/g  
o UPCR > 325 mg/g  
o New onset of hematuria 
(defined as ≥ 5 RBC/hpf)  
 To align the renal stoppi[INVESTIGATOR_671543] -sense 
oligonucleotides conducted by [CONTACT_671577] 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
12 PROTOCOL SYNOPSIS  
Protocol Title  A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 
703802 (AKCEA-ANGPTL3-L Rx) Administered Subcutaneously (SC) to Subjects with 
Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver 
Disease (NAFLD)  
Study Phase  2 
Indication  Subjects  with Hypertriglyceridemia  
Primary Objective(s)  To assess the effect of different doses and dosing regimens of ISIS 703802 on reduction 
in fasting triglycerides (TG)  
Secondary Objective(s)  To evaluate the safety and tolerability of ISIS [ADDRESS_907236] of ISIS 703802 on changes from Baseline at End -of-Treatment on 
glucose and lipid metabolism, and liver fat  
To evaluate pharmacokinetics (PK) of ISIS [ADDRESS_907237] of ISIS 703802 on changes from Baseline on biomarkers related to 
liver inflammation, adipokines and body composition  
Study Design  This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.  
Approximately 96  subjects will be randomized in a 3:1 ratio to receive ISIS 703802 or 
placebo.  The sample size was determined to provide statistical power for ef ficacy 
assessments.  Study Drug (ISIS 703802 or placebo) will be administered SC every week 
or every [ADDRESS_907238]-treatment follow -up period.  
The primary safety and efficacy analysis time point is at Week 27 for subjects  who 
received weekly dosing (Cohort A) and at Week 25 for subjects who received every 
4-week dosing (Cohorts B and C).  
Number of Subjects  Approximately [ADDRESS_907239] given written informed consent (signed and dated) and any 
authorizations required by [CONTACT_10523] 
2. Males or females aged ≥ 18 and ≤ 70 years old at the time of informed consent  
3. Plasma TG at Screening > 150 mg/dL and at qualification  of > 150 mg/dL  
4. Documented history of hepatic steatosis as determined by [CONTACT_9661] (CT scan, 
MRI, FibroScan, or US) suggesting liver fat > 8%, or positive ultrasound at 
Screening  
5. Baseline MRI indicating hepatic fat fraction (HF F) > 8%  
6. Clinically confirmed diagnosis of T2DM  
a. Hemoglobin A1c > 6.5 and ≤  10% at Screening  
b. On a stable dose of oral glucose-lowering medication (ie metformin, 
sulfonylureas, DPP -4 inhibitors,  SGLT2 inhibitors) for at least 3 months 
before Screening and plan to remain on the same medication for the 
duration of the study  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
13 7. Body mass index between 27- 40 kg/m2, inclusive, at Screening  
8. If taking lipid lowering medication, subjects must be on a stable dose for at least 
[ADDRESS_907240] dose of study drug and plan to remain on the s ame 
medication for the duration of the study  
9. Females:  must be non-pregnant and non -lactating and either;  
a. surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral 
salpi[INVESTIGATOR_1656], bilateral oophorectomy);  
b. post-menopausal (defined as 12 months of spontaneous amenorrhea in 
females > 55 years of age or, in females ≤ 55 years, 12 months of 
spontaneous amenorrhea without an alternative medical cause and FSH 
levels in the postmenopausal range for the laboratory involved);  
c. Abstinent* or ; 
d. if engaged in sexual relations of child- bearing potential, agree to use 2 
highly effective contraceptive methods (refer to Section 6.3.1) from the 
time of signing the informed consent form until at least [ADDRESS_907241] dose of Study Drug ( ISIS 703802 or placebo)  
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with 
the preferred and usual lifestyle of the subject .  Periodic abstinence (e.g., 
calendar, ovulation, symptothermal, post -ovulation methods), declaration of 
abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception 
10. Males must be surgically sterile or, if engaged in sexual relations with a female of child-bearing potential, the subject must be using an acceptable contraceptive 
method (refer to  Section 6.3.1)  from the time of signing the informed consent 
form until at least [ADDRESS_907242] dose of ISIS 703802 
Exclusion Criteria  
1. Type 1 diabetes mellitus  
2. Active chronic liver disease, alcoholic liver disease, Wilson’s disease 
hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, genetic 
hemochromatosis, known or suspected hepatocellular carcinoma, history of or 
planned liver transplant for end-stage liver disease of any etiology  
3. Documented history of advanced liver fibrosis  
4. History of cirrhosis and/or hepatic decompensation including asc ites, hepatic 
encephalopathy, or variceal bleeding  
5. Uncontrolled hypertension (systolic > 160 or diastolic > 100 mm Hg)  
6. History of acute kidney injury within [ADDRESS_907243]  unsuitable for inclusion, including the fol lowing:  
a. Positive test (including trace) for blood on urinalysis.   In the event of a 
positive test, eligibility may be confirmed with urine microscopy showing ≤  5 
red blood cells per high power field  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
14 b. Urine protein/creatinine ratio (UPCR) ≥ 0.25 mg/mg. In th e event of a UPCR 
above this threshold, eligibility may be confirmed by a quantitative total urine 
protein measurement of ˂ 300 mg/24-hr  
c. Estimated GFR ˂ 60 mL/min/1.73 m2 (as determined by [CONTACT_474263] -Epi[INVESTIGATOR_368010] (CKD -EPI) Equation)  
d. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > [ADDRESS_907244] 
e. Bilirubin > ULN, unless prior diagnosis and documentation of Gilbert’s 
syndrome in which case total bilirubin must be ≤ 3 mg/dL  
f. Alkaline phosphatase (ALP) > 1.[ADDRESS_907245] 
g. Platelet count ˂ LLN  
10. Known history of or positive test for human immunodeficiency virus (HIV), 
hepatitis C or chronic hepatitis B  
11. Uncontrolled hyper - or hypothyroidism . Subjects on dose stable replacement 
therapy for at least 3 months prior to Screening will be allowed 
12. History of clinically significant acute cardiac event within 6 months before Screening (includes stroke, transient ischemic attack, and coronary heart dis ease 
[angina pectoris, myocardial infarction, revascularization procedures])  
13. History of heart failure with NYHA greater than Class II  
14. Current acute or  chronic inflammatory disease  
15. Hypersensitivity to the active substance or to any of the excipi[INVESTIGATOR_840]  
16. Active  untreated mental disorder or depression. Subjects  who are on a stable 
dose of medication (excluding atypi[INVESTIGATOR_16709]) for at least 6 months before 
screening and whose treating physicians consider them to be mentally stable may 
be enrolled  
17. Any major surgery including b ariatric surgery within 3 months of Screening 
18. Weight change >  5% within 3 months before Screening or during diet run in 
period  
19. Currently taking parenteral or chronic oral corticosteroids, amiodarone, tamoxifen, 
obeticholic acid, atypic al antipsychotics, HIV protease inhibitors, or 
ursodeoxycholic acid  
20. Alcohol consumption >  21 units of alcohol per week for men and >  14 units of 
alcohol per week for women over a two-year  time frame prior to the Baseline MRI 
eligibility (One drink "unit" or one standard drink is equivalent to a [ADDRESS_907246] liquor)   
21. Malignancy within [ADDRESS_907247] -Treatment Follow -up Period, during which regular clinical 
monitoring will be performed  
24. Use of insulin  or insulin analogs, GLP -1 agonists, and PPAR ᵞ agonists 
(pi[INVESTIGATOR_512557])  
25. Treatment with another investigational drug, biological agent, or device within 1 month of Screening, or 5 half -lives of investigational agent, whichever is longer  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
15 26. Treatment with any non -Akcea/non -Ionis oligonucleotide (including small 
interfering ribonucleic acid [siRNA]) at any time or prior treatment with an Ionis 
oligonucleotide or siRNA within [ADDRESS_907248] 
previously received only 1 dose of an Ionis oligonucleotide as part of a clinical 
study may be included as long as ≥ [ADDRESS_907249] elapsed since dosing 
27. Blood donation of 50-499 mL within 30 days of Screening or of > [ADDRESS_907250] any metal implant ( e.g., heart pacemaker, rods, screws, aneurysm 
clips)  that contraindicates MRI procedures  
30. Have any other conditions, which, in the opi[INVESTIGATOR_671544], or could interfere with the 
subject  participating in or completing the study  
Treatment Groups   Subjects will be randomized to 3 parallel cohorts:  
Cohort A (n = 32): Subjects will be randomized 3:1 to receive 20 mg ISIS 703802 or 
placebo SC once every week for 26 doses.  
Cohort B (n = 32): Subjects will be randomized 3:1 to receive 40 mg ISIS 703802 or 
placebo SC once every 4 weeks for 6 doses.  
Cohort C (n = 32): Subjects will be randomized 3:1 to receive 80 mg ISIS 703802 or 
placebo SC once every 4 weeks for 6 doses.  
Cohort  Treatment  # Doses  Total Study Drug  
A 20 mg ISIS 703802 or placebo  
(Every week) 26 520 mg  
B 40 mg ISIS 703802 or placebo  
(Every 4 weeks)  6 240 mg  
C 80 mg ISIS 703802 or placebo  
(Every 4 weeks)  6 480 mg  
 
Study Drug Dosage and Administration  The Sponsor will provide ISIS 703802 in a single use vial with a concentration of 100 
mg/mL and matching volume placebo:  
Cohort A: 20 mg every week of ISIS 703802  or placebo (0.2 mL)  
Cohort B: 40 mg every 4 weeks of ISIS 703802  or placebo (0.4 mL)  
Cohort C: 80 mg every 4 weeks of ISIS 703802  or placebo (0.8 mL)  
All doses will be given by [CONTACT_10530].  Self -administration will be allowed after 
appropriate training of subject and/or caregiver.  
Rationale for Dose and Schedule 
Selection  The Phase 1 program evaluated ISIS 703802 doses of 10 mg, 20 mg, 40 mg and 60 mg 
given weekly for 6 weeks that were found to be generally well -tolerated and to induce 
clinically -relevant reductions in lipid parameters .  The range of dosing proposed for the 
present study will provide the equivalent drug exposure of 10 mg (from 40 mg monthly), 
and 20 mg (from 20 mg weekly and 80 mg monthly) administered weekly, and is predicted (based on modelling of PK/PD data obtained in Phase 1 study) to result in 
mean reductions from Baseline  in TGs ranging from approximately 45 to 55% at 
steady -state.  
Adjustment of Dose or 
Treatment Schedule  Dose adjustments, including dose interruptions, and/or decreasing the dose and dose 
frequenc y may be allowed for safety or tolerability after consultation with the Sponsor 
Medical Monitor.   
ISIS [ADDRESS_907251] of the following periods:  
• A Screening Period  (up to 5 weeks), including a 4-week diet stabilization phase, 
where appropriate  
• A Treatment Period ( 26 week s) during which Study Drug will be administered 
per assigned cohort by [CONTACT_10530]  
• A Post -treatment Follow -up Period  (13 weeks)  
During the Screening Period, subject will be advised to maintain diet and exercise 
routines and remain on a stable regimen of diabetes and lipid medications (if they are 
already taking any).  As part of the Screening Period, subjects not already on a stable diet 
will have 4 weeks of diet run-in, followed by a qualification visit  during which final eligibility 
assessments will be performed . Subjects  on stable diet known to the investigator and 
followed at the site may go from Screening to qualification without a 4-week diet 
stabilization phase. At the qualification visit TGs will be measured. MRI will be obtained 
during screening  once all other eligibility criteria are met to assess liver fat content.   
Subjects  meeting eligibility criteria at S creening and having a qualifying TG and MRI, 
defined as having greater than  8% liver fat assessed by [CONTACT_9268] -PDFF (via central reviewer) 
will return  to the clinic on Day 1. TG and MRI results must be available prior to 
randomization and administration of the first dose of study drug. 
Subjects  assigned to Cohort A will receive a single SC dose of ISIS 703802 or placebo 
every week  for a total of 26 doses .  Subjects  assigned to Cohorts B and C will receive a 
single  SC dose of ISIS 703802  or placebo every 4 weeks  for a total of 6 doses .  Subjects  
will return regularly for outpatient visits throughout the treatment period according to the 
Schedule of Procedures  (Appendix A) . 
Following the end of the treatment period, s ubjects will then enter a 13-week Post -
Treatment Follow -up Period and will return to the Study Center for outpatient evaluations 
according to the Schedule of Procedures  (Appendix A) .  
Blood and urine samples will be collected regularly throughout the study for safety, 
efficacy, and PK analysis.  Appendix B  shows a list of analytes required for the study and 
Appendix C  details the PK sample schedules.  
Safety and Tolerability 
Evaluations  Safety and tolerability assessments include: adverse events, vital signs and weight, 
physical examinations, clinical laboratory tests, ECGs and use of concomitant medications.   
Safety and tolerability results in patients dosed with ISIS 703802
 will be com pared with 
those dosed with placebo.  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
17 Efficacy and Safety 
Evaluations  The primary analysis time point is at Week 27 for subjects who received every week 
dosing (Cohort A) and Week 25 for subjects who received every 4-week dosing (Cohorts 
B and C).  
Primary endpoint:  
• Percent change in fasting TG level from Baseline at the primary analysis time 
point  
Secondary endpoints : Evaluate the effect of ISIS 703802 on changes from Baseline at 
the primary analysis timepoint in:  
• Absolute and percentage change in ANGPTL3 protein, TC, LDL-C, HDL -C, 
VLDL -C, Non -HDL -C, ApoB  (ApoB -48, ApoB -100) , ApoCIII, ApoAI, FFA, Lp(a)  
• Absolute change in fasting plasma glucose , HbA1c, fasting insulin HOMA -IR, 
fructosamine and glycated albumin  
• Absolute and percent change in weight, S BP and DBP  
• Absolute and percent change in hepatic fat fraction (HFF) by [CONTACT_9268] -PDFF  
• Proportion of subjects  reaching hepatic fat fraction (HFF) ≤ 8% by [CONTACT_9268] -PDFF  
• Absolute change in Fatty Liver Index (FLI)  
• Absolute change in ALT and AST  
• Adipokines and related metabolic markers  such as leptin, adiponectin, 
phospholipi[INVESTIGATOR_805] (e.g. ceramides, sphingolipi[INVESTIGATOR_805], diacylglycerol)  
• Body composition as measured by [CONTACT_671578] (SAT) and visceral adipose tissue (VAT) , waist circumference, WHR 
(waist -to-hip ratio), and BMI  
 
  
Pharmacokinetic 
Evaluations  Plasma samples will be taken from all subjects for the measurement of ISIS [ADDRESS_907252] -treatment follow -up period.  
Plasma sample collection time points are detailed in Appendix A  and C.  In addition, in a 
subset of subjects (approx imately 12 subjects per cohort), more frequent plasma samples 
will be taken following the first administration and Day 176 (for Cohort A) or Day 141 (for 
Cohorts B and C) dose to determine PK parameters.  Plasma sample collection time points are detailed i n 
Appendix A  and C. 
The plasma ISIS [ADDRESS_907253] 
immunogenicity status.  

ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
18 Statistical 
Considerations  The primary efficacy analysis for the primary endpoint will be the pairwise comparison of percent change from Baseline to the primary analysis time point in fasting TG between 
ISIS 703802 treated groups and placebo group in the Full Analysis Set.  
The data will be analyzed using an ANCOVA model with the Baseline TG level as a 
covariate.  
Dose selection for the further development will be based on the following efficacy and safety considerations; more than 1 dose may meet these criteria.  An effective dose, or dose regimen, will be one that achieves a clinically -meaningful reduction in plasma TG 
levels.  Safety will be evaluated on the basis of incidence of  expected and unexpected 
treatment -related SAEs, and other specific safety considerations including the incidence 
of platelet reductions.  
Sample Size Considerations:  
Subjects in the placebo arm will be pooled for the statistical analysis in order to compar e 
active and control arms. Therefore, each of the [ADDRESS_907254] 24 patients. Considering 
10% dropouts, [ADDRESS_907255]:  
• A treatment difference in mean triglycerides of 50% based on a between- patient 
standard deviation of 46% (Jani et al. 2014)  and a two-sample t -test with an 
unadjusted alpha level of 0.05 with 93% power.  
• A treatment difference in mean liver fat of 4.75% based on a between-patient 
standard deviation of 3.96% (Tiikkainen et al. 2004
) and a two -sample t -test with an 
unadjusted alpha level of 0.05 with 96% power.  
Sponsor/Collaborator  Akcea Therapeutics , Inc./Ionis Pharmaceuticals , Inc.  
  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
19 STUDY DESIGN AND TREATMENT SCHEMA  
 
SCREENING PERIOD  
Weeks -5 to 0  
TREATMENT PERIOD  
Weeks 1 to 21/26* 
Dosing per assigned cohort:  
Cohort A : (n = 32):  20 mg ISIS 703802or placebo 
SC once every week for 26 doses.  
Cohort B:  (n = 32): 4 0 mg ISIS 703802 or placebo 
SC once every 4 weeks for 6 doses.   
Cohort C :  (n = 32): 80 mg ISIS 703802 or placebo 
SC once every 4 weeks for 6 doses.   
Routine safety assessments :  PK and PD/efficacy 
assessments at specified time points  
* The primary analysis time point  is at Week 27 
for patients who received every week  dosing 
(Cohort  A) and Week 25 for patients who received 
every 4 -week dosing (Cohorts B and C). 
POST -TREATMENT 
EVALUATIONS  
[ADDRESS_907256] dose of Study Drug  
Cohorts B & C - Weeks 6, [ADDRESS_907257] dose of Study Drug  
EARLY 
TERMINATION 
(ET) 
Follow ET  visit in 
Schedule of Procedures;  
  
Patient strongly 
encouraged to visit clinic 
for post -treatment 
assessments  
END- OF-STUDY 
PROCEDURES  
Early Termination or 3rd Follow -
Up visit (13 Weeks after end of 
treatment period) 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
20 STUDY GLOSSARY 
Abbreviation  Definition  
2′-MOE  2′-O-(2-methoxyethyl)  
AE adverse event  
ISIS 703802 Antisense inhibitor of ANGPTL3 
ALP  alkaline phosphatase 
ALT  alanine aminotransferase (SGPT)  
ANA  antinuclear antibody  
ANCOVA  Analysis of Covariance 
ANGPTL3  Angiopoietin like [ADDRESS_907258]  aspartate aminotransferase (SGOT)  
AUC  area under the curve  
AUC t area under the plasma concentration -time curve from time 
zero to time t  
Bb complement F actor Bb (activated complement split product) 
βhCG beta-subunit of human chorionic gonadotropin (pregnancy 
test) 
bp Base pair  
BP blood pressure 
BUN  blood urea nitrogen 
C Centigrade  
C5a complement Factor C5a (activated complement split product) 
C
max maximum concentration  
CBC  complete blood count 
CL systemic clearance  
CMV  Cytomegalovirus 
CRF  case report form  
CRP  C-reactive protein  
CS clinically significant  
CT computed tomography 
ISIS [ADDRESS_907259] 
HIV human immunodeficiency virus 
HOMA- IR Homeostatic Model Assessment Insulin Resistance  
HR heart rate  
hr, hrs hour(s) 
hsCRP  CRP measured by [CONTACT_671579] [ADDRESS_907260] 
IL-6 interleukin -6 
IL-8 interleukin -8 
IL-10 interleukin -10 
IL-12 interleukin -12 
IL-12p40p70 interleukin -12 p40 (40 kDa) and p70 (70 kDa) subunits  
INR international normalized ratio  
IRB Institutional Review Board  
ISIS 703802 antisense inhibitor of ANGPTL3 
IV Intraven ous(ly) 
IXRS  Interactive voice/internet response system  
kg Kilogram  
L Liter 
LDH  lactate dehydrogenase  
LDL-C Low Density Lipoprotein Cholesterol 
LDLR  Low Density Lipoprotein Receptor 
Lp(a)  Lipoprotein (a) 
LVEF  left ventricular ejection fraction  
m2 square meter  
MAD multiple ascending dose 
MCH  mean corpuscular hemoglobin 
MCHC  mean corpuscular hemoglobin concentration 
MCV  mean corpuscular volume 
MedDRATM Medical Dictionary for Regulatory Activities  
mg milligram 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
23 Abbreviation  Definition  
min minute  
mL milliliter  
mm millimeter  
MRI  magnetic resonance imaging  
mRNA messenger ribonucleic acid  
MTD  maximum tolerated dose  
NAFLD  Non Alcoholic Fatty Liver Disease  
NASH Non Alcoholic Steatohepatitis  
NCS  not clinically significant  
NSAID  non-steroidal anti- inflammatory drug  
NYHA  [LOCATION_001] Heart Association  
on study The patient is ‘on study’ from signing of the informed consent 
until their last study visit  
OTC  Over the Counter 
PC personal computer 
pH measure of the acidity or basicity of a solution  
PK pharmacokinetic(s) 
pRBC  packed red blood cells 
PT prothrombin time 
QoL quality of life  
RNase H1  an ubiquitous endonuclease that specifically hydrolyzes the RNA strand in RNA/DNA hybrids  
SAD single ascending dose 
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SAT  Subcutaneous Adipose Tissue 
siRNA small interfering ribonucleic acid  
SC subcutaneous(ly) 
sTNF -R1 soluble tumor necrosis F actor receptor [ADDRESS_907261] Hip Ratio  
WMA  World Medical Association  
 
  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
25 1.  OBJECTIVES  
1.1 Primary Objective(s)  
To assess the effect of different doses and dosing regimens of ISIS 703802 on reduction in 
fasting triglycerides (TG) . 
1.2 Secondary Objective(s)  
To evaluate the safety and tolerability of ISIS 703802.  
To evaluate the effect of ISIS 703802 on changes from Baseline at E nd-of-Treatment on glucose 
and lipid metabolism, and liver fat. 
To evaluate the pharmacokinetics (PK) of ISIS [ADDRESS_907262] of ISIS 703802 on changes from Baseline on biomarkers related to liver 
inflammation, adipokines, and body composition. 
2. BACKGROUND AND RATIO NALE  
2.1 Overview of D isease  
Hypertriglyceridemia  commonly observed in diabetic dyslipi[INVESTIGATOR_671545]-rich very-low- density lipoprotein (VLDL) particles as well as 
impaired intravascular catabolism as a result of decreased lipoprotein  lipase activity (Adiels et al. 
2008). Its etiology includes primary factors (i.e., genetic causes, such as a mutation in a receptor 
protein). S econdary causes of hypertriglyceridemia are far more common and  include metabolic 
synd rome/insulin resistance, obesity, physical inactivity, cigarette smoking, excess alcohol and a 
diet very high in carbohydrates. The guidelines from both the National Cholesterol Education 
Program Adult Treatment Panel III  (NCEP 2002)  and the American Diabetes Association (ADA 
2008)  recommend a target TG level of less than 150 mg/dL to reduce cardiovascular risk  based 
on evidence from clinical studies demonstrating that elevated TG le vels are an independent risk 
factor for atherosclerotic CVD .  
Hypertriglyceridemia associated with insulin resistance and obesity  commonly presents with 
Type 2 diabetes mellitus (T2DM) which  affects more than a third of a billion people worldwide 
and is the leading cause of cardiovascular disease, with estimated annual worldwide health care costs exceeding half a trillion dollars (Dake et al. 2016) . Dyslipi[INVESTIGATOR_671546] 2 
diabetes is very common and a major contributing factor to the development of atherosclerosis.  The phenotype of dyslipi[INVESTIGATOR_671547] (hypertriglyceridemia), reduced HDL -C, smaller LDL particles, but with relatively similar 
LDL- C levels com pared with the general population.  
The association  of diabetic dyslipi[INVESTIGATOR_035],  insulin resistance, and excess lipid storage in the form 
of visceral obesity and hepatic steatosis has long been recognized  (Shulman 2014) . Hepatic 
steatosis also known as non- alcoholic fatty liver disease (NAFLD) results from increased hepatic 
uptake of free fatty acids derived mainly from the hydrolysis of adipose- tissue triglycerides 
(increased because of insulin resistance) but also from dietary chylomicrons overload and hepatic 
lipogenesis.  Insulin resistance is one of the key pathogenic factors in the development and 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
26 progression of non- alcoholic fatty liver disease and also plays a major role in the development of 
the metabolic syndrome and cardiovascular disease ( Targher  et al.  2010) . Worldwide prevalence 
of NAFLD/NASH is reported to range from 6.3% to 33% with a median of 20% in the general 
population. The estimated prevalence of NASH is lower, ranging from 3 to 5 % ( Vernon et al. 
2011).  In one study t he prevalence of NAFLD in high -risk groups such as in T2DM with 
dyslipi[INVESTIGATOR_671548]  69% (Leite et al. 2009 ) which was higher than  the 
50% prevalence reported in patients with dyslipi[INVESTIGATOR_671549]  (Assy et al. 2000) . Despi[INVESTIGATOR_88776], there are currently no approved 
pharmacological therapi[INVESTIGATOR_671550] , 
highlighting the urgent need to develop effective therapeutic strategies for this common 
condition. 
2.2 T herapeutic Rationale 
In humans, loss of function mutations within the ANGPTL3  gene give rise to familial combined 
hypolipi[INVESTIGATOR_035]  (FHBL2) , characterized by [CONTACT_671580],  total cholesterol, 
LDL-C, and HDL -C (Minicocci et al. 2012) . Homozygous individuals with complete ANGPTL3  
deficien cy showed the full combined hypolipi[INVESTIGATOR_671551]3  deficiency showed a more attenuated phenotype. Of note, FHBL2 
homozygous were not affected by [CONTACT_37110], showed lower plasma levels of insulin and lower 
degree o f insulin resistance as estimated by [CONTACT_14785] -IR (Robciuc et al. 2013) .   
ANGPTL3 protein is produced exclusively in the liver, where its expression is downregulated by 
[CONTACT_525646] ( Inukai et al. 2004) . Hepatic specific knock -down of ANGPTL3 mRNA is 
associated with a reduction in plasma triglycerides due to increased lipoprotein lipase ac tivity as 
well as decreased hepatic VLDL triglyceride secretion.  Because ANGPTL3 is produced by [CONTACT_671581], which does not express LPL, it is thought to function as an endocrine rather than paracrine factor with insulin sensitizing effects that go bey ond the liver.  In fact, insulin 
sensitization has been  shown in patients with ANGPTL3 gene mutations  as well as in 
ANGPTL3 -deficient mice, in which increased uptake of fatty acids into oxidative tissues such as 
muscle and brown adipose tissue led to decre ased uptake of fatty acids and increased uptake of 
glucose in white adipose tissue ( Wang et al. 2015 ). Suppression of hepatic ANGPTL3 protein 
production in mice resulted in significant reductions in levels of triglycerides, LDL cholesterol, non-HDL cholesterol, and VLDL cholesterol and these favorable effects were associated with 
decreased liver triglyceride content, increases in insulin sensitivity, and a reduction in atherosclerosis progression ( Graham et al. 2017 ).    
Treatment with ISIS 703802 ( AKCEA- ANGPTL3 -L
Rx) would be expected to lower  the hepatic 
expression of ANGPTL3 protein and result in lowering of the levels of triglyceride -rich 
lipoproteins and LDL -C, increased HDL -C, improv ed glycemic control  and ameliorated  insulin 
resistance in T2DM patients , leading to decreas ed liver fat content in NAFLD  and ult imately,  
reduced overall risk of coronary artery disease.  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
27 2.3 ISIS 703802 
2.3.1 Mechanism of Action  
ISIS 703802 is a second -generation ASO drug targeted to ANGPTL3 that has been covalently 
bonded to triantennary N- acetyl galactosamine (GalNAc), a high -affinity ligand for the 
hepatocyte- specific asialoglycoprotein receptor (ASGPR) to form an ASO -GalNAc conjugate.  
This GalNAc -conjugate approach results in enhanced ASO delivery to hepatocytes versus 
non-parenchymal cells and has increased ASO potency by [CONTACT_3450] 10 -fold in mice  
(Prakash  et al. 2014 ). The ASO portion of ISIS 703802 is complementary to a region within the 
ANGPTL3 messenger ribonucleic acid (RNA) (mRNA) coding sequence, and binds to the 
mRNA via Watson and Crick base pairing. The hybridization (binding) of ISIS 703802 to the cognate mRNA results in the Ribonuclease H1 (RNase H1) -mediated degradation of the 
ANGPTL3 mRNA, thus preventing production of the ANGPTL3 protein.  Maximal 
antisense-mediated reduction of target mRNA levels is typi[INVESTIGATOR_37497] 90% of control levels in sensitive tissues (Crooke and Bennett 1996; Zhang et al. 2010).   Furthermore, reduction 
in target  mRNA levels using this approach correlates directly with a subsequent reduction in 
target protein levels.  
2.3.2 Chemistry  
Chemically, ISIS 703802
 is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by [CONTACT_19966] (mixed backbone design). The mixed backbone design reduces the total number of phosphorothioa te linkages in 
the MOE -modified regions, which reduces non-specific interactions with proteins and further 
enhances the potency of GalNAc  conjugated ASOs.  The nucleotide sequence of ISIS 703802
 
(Figure 1 ) is complementary to a 20 -nucleotide stretch within Exon 6 of the ANGPTL3 mRNA 
coding sequence at position 1169-1188 bp. 
Structurally, the oligonucleotide has 4 regions.  Two (2) of them, the 5 nucleotides at the 5′ end 
and the 5 nucleotides at the 3′ end, are composed of 2′- O-(2-methoxyethyl) ( 2′-MOE) -modified 
ribonucleotides. These MOE-modified nucleotides confer (1) increased affinity for the target mRNA (Altman n et al. 1996; McKay et al. 1999),  (2) increased resistance to exonucleases and 
endonucleases (thereby [CONTACT_37759]) (Geary et al. 2003 ), and (3) amelioration of 
some of the high dose toxicities thereby [CONTACT_671582] (DNA) (Henry et al. 2008).  The third region, the central portion of the oligonucleotide, is composed of 
10 oligodeoxynucleotides. This chimeric design is called a MOE- Gapmer, and ISIS 703802 
employs this chimeric structure to enable the use of the RNase H1 mechanism for antisense 
activity.  This is because while the 2′-MOE modification confers increased stability and affinity, it does not support RNase H1 catalyzed cleavage of RNA hybridized to 2′- MOE -modified 
nucleotides ( McKay et al. 1999).  This is caused by [CONTACT_671583] 2′- alkoxy:RNA hybrids that are not recognized by [CONTACT_37695] H enzymes (Inoue et 
al. 1987; Monia et al. 1993).  By [CONTACT_37761] 2′ -MOE modification to nucleotides flanking the 
phosphorothioate oligodeoxynucleotide core, the beneficial attributes of the 2′- MOE chemistry 
are preserved while also retaining RNase H1 recognition. The fourth region is comprised of a triantennary cluster of N -acetyl galactosamine (GalNAc) sugars which is linked to the 5ʹ end of 
ISIS 703802 via a phosphodiester linkage. The GalNAc cluster is a high affinity ligand for the 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
28 asialoglycoprotein receptor (ASGPR), a receptor expressed primarily o n the surface of liver 
hepatocytes (Stockert 1995).  The GalNAc cluster enhances delivery of ISIS 703802 to liver 
hepatocytes over other cell types and enhances potency. After internalization into cells, the 
GalNAc cluster is  metabolized to release ‘free ASO’ inside the cell (Prakash et al. 2014).  
 
Figure 1 Design of Chimeric 2ʹ-MOE Phosphorothioate Oligonucleotides  
(MOE -Gapmer).  The sequence of ISIS 703802 is shown . 
2.3.3 Preclinical Experience  
Detailed information concerning the preclinical studies conducted with ANGPTL3 ASOs  can be 
found in the Investigator’s Brochure. A summary is included below. 
[IP_ADDRESS] Preclinical  Pharmacology 
The pharmacology of ANGPTL3 ASOs has been examined in multiple in vitro  cell lines where 
specific and dose-dependent reduction of ANGPTL3 mRNA and protein was clearly 
demonstrated, resulting in reductions in apoB secreted protein. The pharmacology of ISIS 563580, an unconjugated 2′- MOE modified ASO that has the same base sequence as ISIS 
703802, has been studied at doses higher than planned for ISIS 703802. 
ISIS 563580 has been explored in human ANGPTL3 transgenic mice, wherein liver mRNA and 
plasma ANGPTL3 protein levels were reduced upon treatment with ISIS  563580. 
Reductions in murine ANGPTL3 mRNA and protein were routinely observed in all mouse 
models treated with a murine -specific ANGPTL3 ASO. Pharmacology studies were done with 
Ldlr
-/- mice fed a hypercholesterolemic diet known to develop elevated LDL-C, TG, and 
atherosclerosis, as well as features of metabolic syndrome (hyperglycemia and hyperinsulinemia) (Huszar et al. 2000; Schreyer et al. 2002; Tsuchiya et al. 2012).  Treatment of mice with a 
murine- specific ANGPTL3 ASO resulted in improvement in all of the aforementioned lipid and 
metabolic endpoints compared to controls. In all mouse models tested, total plasma cholesterol, LDL-C, TG, and non-esterified fatty acids (NEFA) have been shown to be consistently reduced upon treatment with ANGPTL3 ASOs, while HDL -C is modestly decreased in wild type mice 
(- 22%), and either stable or increased in others. While a clear mechanistic understanding of 
2ʹ-MOE  
 2ʹ-MOE  
 2ʹ-Deoxy  
GalNAc = THA -GalNAc cluster  
2ʹ-MOE = 2ʹ-methoxyethyl RNA  
2ʹ-Deoxy = DNA  
s = phosphorothioate linkage  
o = phosphodiester linkage  
(RNase H1 sensitive)  
GalNAc  
 GsGoAoCoAo 
TsTsGsCsCsAsGsTsAsAs 
ToCoGsCsA 
ISIS [ADDRESS_907263] that HDL function is maintained. 
Administration of ISIS 703802, a human specific , GalNAc conjugated , ANGPTL3 ASO, to 
human ANGPTL3  transgenic mice led to significant, dose-dependent reductions in hepatic 
ANGPTL3 mRNA. In diet c hallenged mice, administration of ISIS 731875, a mouse- specific 
and GalNAc-modified ASO targeting ANGPTL3, led to dose-dependent reductions in both 
hepatic ANGPTL3 mRNA and plasma ANGPTL3 with concomitant reductions in plasma TG and cholesterol. Importantly, the potency and the lipid- lowering effects of the ANGPTL3 ASO 
were independent of diet. 
Finally, administration of a mouse- specific ANGPTL3 ASO to western diet fed Ldlr
-/-, a mouse 
model of FH, also led to significant reductions in hepatic ANGPTL3 mRNA and plasma 
ANGPTL3 protein with concomitant reductions in plasma TG and LDL- C that were similar to 
what was observed in wild type western diet fed mice, indicating that the absence of Ldlr does not affect the ASOs potency or lipid- lowering effects. This suggests that administration of 
ANGPTL3 ASO administration is a promising target for clinical study in familial hypercholesterolemia patients.  
While formal pharmacology studies have not been conducted in the monkey with the human ANGPTL3 ASO, hepatic mRNA ex pression has been shown to be reduced by [CONTACT_726] 60% in 
cynomolgus monkeys, the same model used to conduct the toxicology evaluation. 
[IP_ADDRESS] Preclinical Toxicology 
General toxicology studies for ISIS 703802 consisted of sub-chronic (16-week) and chronic 
(26- or 39- week) toxicity studies CD -1 in mice and cynomolgus monkeys. Since ISIS 703802 is 
not fully complementary to the mouse ANGPTL3 transcript, treatment group receiving a mouse- specific inhibitor (ISIS  731875) w as also included in the mouse study. Please refer to the 
Investigator Brochure for a detailed description of the preclinical toxicology and pharmacokinetics with ISIS 703802. 
Pharmacokinetic data confirmed continuous and dose-dependent exposure to ISIS 703802.  An estimated liver and plasma terminal elimination half -life values of approximately 1 week  and 
3-4 weeks for 2  mg/kg and 35 mg/kg, respectively, were observed in monkeys. The most 
noteworthy findings observed in mice and monkeys following ISIS [ADDRESS_907264] noteworthy finding in the monkey was the kidney a lteration (hypoalbuminemia and 
proteinuria) seen in one early- sacrifice animal from the 16 -week study at 35 mg/kg/week, a dose 
equivalent to at least ~190 -fold of the 40 mg weekly clinical doses by [CONTACT_671584].  Non-dose 
dependent increases in renal protein excretion (up to 2.2-fold in quantitative urine protein, 
protein/creatinine ratio or urine albumin) were also observed at 8 and/or 35 mg/kg/week (> ~ 30 to  190-fold of the 40 mg weekly clinical doses by [CONTACT_671584] ) at the 16 -week 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
30 scheduled terminal necrop sy. However, Similar kidney alterations were not seen at the 6 -week 
interim at any doses or  in the 39- week chronic mon key study up to 12 mg/kg/week (> ~200-fold 
of the 20 mg weekly clinical dose by [CONTACT_671584]).  
Additional findings related  to ASO liver accumulation included increased alanine 
aminotransferase (ALT ), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) at 
≥ 8 mg/kg/week  in the 16 - and 26- week mouse studies and were correlated with individual 
hepatocyte necrosis  (minimal to mild)  in mouse liver.  Those changes were most prominent in 
the high dose groups (50 and 24 mg/kg/week for the 16- and 26-week studies, respectively). 
Conversely, no changes in liver enzymes were observed in monkeys from the 39- week toxicity 
study up to 12 mg/kg/week. In the 16- week monkey study, increase in ALT was only evident in 
one early -sacrifice animal at 35 mg/kg/week , and non- statistically  significant increases in ALT 
(< 2-fold of the prestudy Baseline ) were also observed in the interim- and terminal- sacrifice 
animals at ≥  8 mg/kg/week but showed no microscopic correlates or dose-dependency. 
Given  the spectrum and severity of the test article -related clinicopathologic alterations present in 
monkeys at doses ≤ 12mg/kg/week (> ~100-fold of the 40 mg weekly clinical dose by [CONTACT_671584]) during the 39-week treatment phase, none would be regarded to represent an adverse effect (Dorato and Engelhardt 2005; Everds et al.  2013).  Considering the monkey to be the most 
relevant species, these data have characteriz ed the safety profile and established appropriate 
therapeutic margins for the clinical evaluation of ISIS 703802 in humans. 
2.3.4 Clinical Experience  
Detailed information co ncerning the clinical studies conducted with ISIS 703802 can be found in 
the Investigator’s Brochure.  A summary is included below. 
The Study Drug, ISIS 703802, is being evaluated in Phase 1 in the clinical setting with single 
doses up to 120 mg and multiple doses up to 60 mg (once per week for 6 weeks). The parent 
drug ISIS  563580, an unconjugated 2′- MOE modified ASO that has the same base sequence as 
ISIS 703802, was also evaluated in a blinded, placebo-controlled Phase 1 study. 
An interim analysis of ISIS 703802 Phase 1 SAD/MAD Study (ISIS 703802- CS1) was 
performed in 44 subjects administered  single ascending (20, 40 and 80 mg) or multiple 
ascending doses (10, 20, 40 and 60 mg/week for 6  weeks) . Twelve participants were randomly 
assigned to single -dose groups (9 to active-agent dose groups and 3 to the placebo group) and 
32 were randomly assigned to multiple-dose groups (24 to active-agent dose groups and 8 to the 
placebo group). The main endpoints of the study were safet y, tolerability, pharmacokinetics, 
pharmacodynamics and changes in lipi[INVESTIGATOR_6520]. After 6 weeks of treatment, persons in the multiple dose groups treated with ISIS 703802 had dose-dependent reductions in levels of ANGPTL3 protein (reductions of 46.6 to 84.5% from Baseline, P< 0.01 for all doses vs. placebo 1.6%) and in levels of triglycerides (reductions of 33.2 to 63.1% vs placebo 11.4%), LDL cholesterol (1.3 to 32.9% vs placebo 13.6%), very-low-density lipoprotein cholesterol (27.9 to 60.0% vs placebo 4.0%), non–high -density lipoprotein cholesterol (10.0 to 36.6% vs placebo 
9.1%), apolipoprotein B (3.4 to 25.7% vs placebo 11.0%), and apolipoprotein C-III (18.9 to 58.8% vs placebo 3.1%). There were no serious adverse events documented during the trial. No protocol-defined injection -site reactions were reported. Of those participants who received the 
multiple -dose regimen, three reported headache (one who received placebo and two who 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
31 received ISIS 703802) and three reported dizziness (two who received placebo and one who 
received ISIS 703802). There was no clinical evidence of prothrombotic effects, bleeding 
epi[INVESTIGATOR_1841], significant decreases in platelet count or thrombocytopenia, or significant changes in 
renal function. One subject in the [ADDRESS_907265] had an ALT of 88 U/L on 
Day [ADDRESS_907266] to follow-up after 5 doses. There were no other discontinuations during the treatment period ( Graham et al. 2017 and data on file ).  
The pharmacokinetics of ISIS 703802 evaluated in Study ISIS  703802- CS1 showed rapid 
absorption following SC administration, with median time to maximum plasma concentrations (T
max) ranging from 1 to 6 hours. Similar T max values were observed at all dose levels. After 
reaching C max, plasma concentrations of ISIS 703802 declined in a m ulti-phasic fashion with a 
rapid disposition phase, followed by a slower elimination phase with terminal elimination half-life of 3 to 5 weeks . The peak (C
max) and total exposur e (AUC) after a single SC dose 
increased approximately dose proportionally from 20 to 40 mg, and greater than dose 
proportionally from 40 to 80 mg, suggesting more efficient tissue uptake at lower doses . After 
single and multiple SC doses in the range of 10 to 60 mg, the C max and AUC increased 
approximately dose proportionally. No accumulation based on C max or AUC was observed after 
6 weekly doses.  
[IP_ADDRESS] ISIS  563580-CS1 Phase 1 SAD/MAD  
In a Phase 1 study, ISIS 563580-CS1, healthy volunteers received subcutaneous administration of ISIS  563580 from 50 to 400 mg as a single dose, or 100 to 400 mg as multiple doses (8 doses 
in 36 days). Overall, the safety findings from this study suggest that ISIS 563580 was not associated with any safety concerns. There wer e 383 adverse events (AE) reported in the 
ISIS 563580-treated subjects of which 363 (95%) were mild in severity. For the multiple-dose 
subjects, the most common treatment- emergent adverse events were AEs at the injection site. 
There was 1 serious adverse event (SAE) in the study of periorbital cellulitis which was considered a medically important event by [CONTACT_671585]. Together, the above suggest that ISIS 563580 was well-tolerat ed at the doses and regimen given, which exceed the dose levels and cumulative 
exposures to be tested in the current study. There were no clinically -relevant changes in 
laboratory assessments and the heparin dose of 80 U/kg was well-tolerated in support of the post- heparin  procedures. ISIS 563580 produced dose-dependent reductions in plasma ANGPTL3 
(up to 93%; group means up to 84%), TG (up to 63%; group means up to 49%) and TC (up to 46%; group means up to 28%) at Day 36 (Brandt et al. 2015).  
2.4 Rationale for Dose and Schedule of Administration 
The Phase 1 program evaluated ISIS 703802 doses of 10 mg, 20 mg, 40 mg and 60 mg given 
weekly for 6 weeks that were found to be generally well -tolerated and to induce clini cally -
relevant reductions in lipid biomarkers. The range of dosing proposed for the present study will 
provide the equivalent drug exposure of 10 mg (from 40 mg monthly), and 20 mg (from 20 mg weekly and 80 mg monthly) administered weekly, and is predicted (based on modelling of PK/PD data obtained in Phase 1 study) to result in mean reductions from Baseline in TGs 
ranging from approximately 45 to 55% at steady- state.  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
32 Safety data from the available chronic mouse (26-week) and monkey (39- week) studies  suppor t 
once-weekly dosing for chronic administration. The No Adverse Effect Level (NOAEL) for ISIS 
703802 in chronic monkey study was determined to be 12 mg/kg/wk.    
Preclinical pharmacology experiments in Tg-mice and non-human primates demonstrated that 
ISIS 703802 achieved an equivalent reduction in ANGPTL3  plasma concentration to that of the 
unconjugated form, at 1/10th of the unconjugated ASO (ISIS 563580) dose.   
2.5 Benefit -Risk Assessment  
2.5.1 Benefit Assessment  
The current study is designed to evaluate the safety and tolerance of ISIS 703802 in patients with 
hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease 
(NAFLD) . The dose selected is expected to reduce ANGPTL3 and result in a reduction of 
triglycerid e levels , reduction of fat content of the liver  and improvement of glycemic control in 
T2DM patients. We do not know if subjects participating in this study would necessarily benefit from the treatment. However, the increased understanding of the effects of  ISIS [ADDRESS_907267] beyond the end of the study.  
2.5.2 Risk Assessment  
The known potential risks to study participants associated with ISIS 703802 are elaborated on in the Guidance to Investigator section of the Investigator’s Brochure.  
• In preclinical mouse studies, there were increases in ALT and AST and were correlated with increased incidence and/or severity of necrosis of individual hepatocytes (minimal to mild in severity).  Those changes were most prominent in the high dose groups and 
showed no clear progression over time. No increases in liver enzymes were observed in monkeys from the 39-week toxicity study up to 12 mg/kg/week (~200-fold of the 20 mg clinical dose by [CONTACT_671584]). In the 16-week monkey study, increase in ALT was only evident i n 1 early -sacrifice animal at 35 mg/kg/week, no meaningful increase in ALT was 
observed in the schedule sacrificed animals.  
• One subject in the [ADDRESS_907268] increase of ALT, w ithout increase in bilirubin, which was c onsidered a treatment related adverse 
event (AE) by [INVESTIGATOR_678] (PI) a second subject had an ALT of 88 U/L on Day [ADDRESS_907269] treatment which returned to normal range by [CONTACT_2006] 50 and remained normal until the end of the study. There were no other obse rved clinically significant changes in ALT 
and liver function in an ongoing Phase 1 human study ( data on file ).  
• However, to evaluate and mitigate the potential for liver enzyme abnormalities, regular liver chemistry monitoring and stoppi[INVESTIGATOR_671552] 8.5 and 8.6.  
• Injection site adverse events, while not considered safety issues, may affect the ability of the subject to tolerate dosing. Injection site adverse events are the most common side 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
33 effects observed following SC administration of 2′ -MOE ASOs and are dose and 
concentration dependent. Erythema is the most prevalent characteristic. Generally, these 
events are mild and reversible, resolve spontaneously and do not worsen with time.  The histologic findings are consisten t with a local inflammatory response.  Subjects  should be 
informed of the possibility of occurrence of injection site adverse events.  Symptomatic interventions such as icing of the injection site or administration of NSAIDs prior to and/or after the SC dosing have been utiliz ed. 
• 
Although no changes in platelet ( PLT) counts have been observed in  healthy volunteers, 
mouse or monkey in both sub-chronic and chronic studies with ISIS 703802, reductions in 
platelet counts to below the lower limit of normal have been observed after a dministration of 
other ASOs and some subjects have experienced severe thrombocytopenia following 
administration of unconjugated 2′ -MOE ASOs . To evaluate and mitigate the potential for a 
reduction in PLT count, monitoring and stoppi[INVESTIGATOR_671553] 8.5 and 8.6 (Safety Monit oring Rules and Stoppi[INVESTIGATOR_1869]) . 
• No significant changes in serum creatinine, electrolytes, BUN, or urinalysis were 
reported from the interim analysis of the ongoing Phase 1 study (data on file). To 
evaluate and mitigate the potential for a reduction in renal function, since kidneys are an 
organ of high distribution for the studied ASO, monitoring and stoppi[INVESTIGATOR_671552] 8.5 and 8.6 (Safety Monitoring Rules and Stoppi[INVESTIGATOR_1869]) . 
 
While the long- term effect s of reducing ANGPTL3 as a target with the Study Drug are not 
known at this time, there is evidence in literature in humans in whom ANGPTL3 is absent from 
plasma, due to homozygous or compound heterozygous ANGPTL3 mutations, present a pan-hypobetalipoproteinemia phenotype, with generalized and marked decreases (~50% to 70%) in all apoB -100 containing lipoproteins, including VLDL and LDL, as well as HDL.  This clinical 
phenotype has been termed familial combined hypolipi[INVESTIGATOR_671554]2 ( Romeo et al. 2009;  
Musunuru et al. 2010; Martin -Campos et al. 2012; Minicocci et al. 2012; Noto et al. 2012;  
Pi[INVESTIGATOR_671555]. 2012 ; Wang et al. 2015).  Clinical studies in FHBL2 suggest a trend toward lower 
glucose and insulin levels and reported a decrease in VLDL . Remarkably, diabetes and 
cardiovascular disease are reportedly absent from those with homozygous FHBL2 and, no adverse clinical phenotype has been reported to date. 
2.5.3 Overall Assessment of Benefit:  Risk  
ISIS 703802 has demonstrated the ability to reduce ANGPTL3, APOCIII, and TGs  by [CONTACT_92149] 60% in the Phase [ADDRESS_907270] of TG lowering in these subjects . This study will also investigate the potential of ISIS 
703802
 in improving the insulin resistance and glucose profile, and decreasing liver and visceral 
fat content in subjects with high TG levels and T2DM. Although the subjects enrolled in this 
study will not derive long term benefits due to the short duration of the study, the y may derive 
some short term benefit from improved metabolic health  and dietary counselling. The 
information obtained in the c ourse of this study is critical to further development of ISIS 703802 
for hypertriglyceridemia, dyslipi[INVESTIGATOR_035], NAFLD and associated metabolic complications and 
cardiovascular disease.   
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
34 The protocol identifies that potential risks associated  with ISIS 703802 treatment will be 
mitigated  by [CONTACT_671586]. Thus, exposure of subjects in this study is justified by [CONTACT_671587] 703802 (see Section  8.5 Safety Monitoring Rules ). 
3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, dose- ranging study.  
Approximately 96 subjects will be randomized in a 3:1 ratio to receive ISIS 703802 or placebo.  The sample size was determined to provide statistical power for efficacy assessments. Study Drug ( ISIS 703802 or placebo) will be administered SC every week or every [ADDRESS_907271] up to 5 weeks prior to Day 1 (the first day of Study Drug administration). During the 
Screening Period, subjects  will be advised to maintain routine diet and exercise routines and 
remain on a stable regimen of diabetes and lipid medications (if they are already ta king any). As 
part of the Screening Period, following [ADDRESS_907272] a qualification 
visit and, final eligibility assessments will be performed.   Subjects on a stable diet known to the 
investigator and followed at the site may g o from S creening to qualification without a 4- week 
diet run-in. At the qualification visit, TGs will be measured to qualify ( ≥ 150 mg/dL).   MRI will 
be obtained during screening once all other eligibility criteria are met to assess liver fat content.   
Subjects  meeting eligibility criteria at S creening and having a qualifying MRI, defined as having 
greater than  8% liver fat assessed by [CONTACT_9268] -PDFF (via central reviewer) will return to the clinic on 
Day 1.  TG and MRI results must be available prior to randomization and administration of the 
first dose of Study Drug. Subjects  who continue to meet all eligibility criteria at Day 1 will be 
randomized to 1 of the 3 dosing cohorts, with each cohort having a 3:1 ratio to receive ISIS 
703802 or matching volume of placebo, respectively, by [CONTACT_10530]. 
The primary safety and efficacy analysis time point is at Week 27 for subjects  who received 
weekly dosing (Cohort A) and at Week 25 for subjects  who received every 4 -week dosing 
(Cohorts B and C).  
Cohort A (n = 32): 20 mg ISIS 703802 or placebo (3:1) SC once every week for 26 doses. 
Cohort B (n = 32 ): 40 mg ISIS 703802 or placebo SC (3:1) once every 4 weeks for 6 doses. 
Cohort C (n = 32): 80 mg ISIS 703802 or p lacebo SC (3:1) once every 4 weeks for 6 doses. 
Subjects  will return regularly for outpatient visits throughout the treatment period according to 
the Schedule of Procedures ( Appendix A ). 
Subjects  will then enter a [ADDRESS_907273] -Treatment Follow -up Period and will return to the S tudy 
Center for outpatient evaluations according to the Schedule of Procedures (Appendix A ).  
ISIS [ADDRESS_907274] of analytes required for the study and Appendix C  details 
the PK sample schedules.  
3.2 Number of Study Centers  
This is a multicenter, multinational study . 
3.3 Number of Subjects  
Approximately 96 subjects are planned to be enrolled in this study.   
Approximately 32 subjects will be assigned to each cohort, with 24 subjects  receiving ISIS 
703802  and 8 receiving  placebo.  
3.4 Overall Study Duration and Follow- up 
The length of subjects’ participation in the study will be  up to 44 weeks, including an up to 
5-week Screening P eriod, that includes a 4- week diet stabilization/run -in period for subjects not 
already on a stable diet , and a 1-week qualification period, a 26-week treatment period, and a 
13-week post-treatment evaluation period. Please refer to the Schedule of Procedures in 
Appendix A .  
Subjects may be required to attend additional visits for monitoring of adverse events or abnormal investigation results. The frequency of additional monitoring will be determined by [CONTACT_144369]. 
3.4.[ADDRESS_907275] eligibility for the study will be determined within 35 days/ 5 weeks prior to 
randomization. Potential subjects  will report to the Study Center for screening/qualification 
assessments at spec ified intervals within  the 5-week Screening Period as detailed in the Schedule 
of Procedures in Appendix A . 
3.4.[ADDRESS_907276]  will be 13 weeks after the Treatment Period ( last dose 
through one dosing interval post last dose ). 
ISIS [ADDRESS_907277]’s last visit.  
3.[ADDRESS_907278] (DSMB) will be assembled to review safety, 
tolerability and efficacy (as needed) data collected on ISIS 703802 during this study.  Based on 
its ongoing assessment of the safety and tolerability of ISIS 703802, the DSMB will provide recommendations to the Sponsor for modifying, stoppi[INVESTIGATOR_10483].  Details on the safety assessments, frequency of review, meeting schedules and controlled access to unblinded data are outlined in the DSMB Charter and Sta tistical Analysis Plan (SAP).   
4. SUBJECT ENROL LMENT  
4.1 Screening  
Before subjects may be enrolled into the Study, the Sponsor or designee requires a copy of the Study Center’s written independent ethics committee/institutional review board (IEC/IRB) approval of the protocol, informed consent form, and all other subject information and/or recruitment material.  
Subjects must sign the informed consent form before any screening tests or assessments are 
performed. At the time of consent, the subject will be assigned a unique screening number before any study procedures, including screening procedures, are performed. This number will be used 
to identify the subject throughout the trial and must be used on all study documentation related to that subject. At the time of randomization, subjects will be assigned a unique randomization number. The subject  identification number must remain constant throughout the entire trial.  
Subject  identification numbers and randomization numbers, once assigned, will not be reused. 
4.[ADDRESS_907279]  identification number. 
Using an Interactive Web -Response System (IXRS), eligible subjects  will be randomized 
in a 
1:1:1 ratio  to 1 of the 3 parallel-dose cohorts (Cohorts A, B, or C). Within each dose cohort, 
subjects  will be randomized in a 3:[ADDRESS_907280]  has suffered a SAE (as defined in  Section 9.3.3),  
and/or when knowledge of the treatment assignment will impact the clin ical management of the 
subject , the Investigator will have the ability to unblind the treatment assignment for that subject  
using the IXRS . The Sponsor will determine the point at which all treatment assignments will be 
unblinded. The Sponsor or designee will be informed of the unblinding of a subject  within 
24 hours. In addition, all S[LOCATION_003]Rs will be unblinded by [CONTACT_1034]’s or designee’s Drug Safety 
and Quality Assurance personnel for the purpose of regulatory reporting (see  Section 9.2).  
5. SUBJECT ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria within [ADDRESS_907281] given written informed consent (signed and dated) and any authorizations required by [CONTACT_346630] b e able to comply with all study requirements  
2. Males or females aged ≥ 18 and ≤ 70 years old at the time of informed consent 
3. Plasma TG at Screening > 150 mg/dL and at qualification of > 150 mg/dL 
4. Documented history of hepatic steatosis as determined by [CONTACT_671588]  
(CT scan, MRI, FibroScan, or US) suggesting liver fat > 8%, or positive ultrasound at Screening  
5. Baseline MRI indicating hepatic fat fraction (HFF) > 8% 
6. Clinically confirmed diagnosis of T2DM 
a. Hemoglobin A1c > 6.5 and ≤ 10% at Screening  
b. On a stable dose of oral glucose- lowering medication (i .e. metformin, sulfonylureas, 
DPP-4 inhibitors, SGLT2 inhibitors) for at least 3 months before S creening and plan 
to remain on the same medication for the duration of the study 
7. Body mass index between 27- 40 kg/m
2, inclusive, at Screening  
8. If taking lipid lowering medication, subjects must be on a stable dose for at least 
[ADDRESS_907282] dose of S tudy Drug and plan to remain on the same medication for 
the duration of the study 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
38 9. Females:  must be non -pregnant and non- lactating and either;  
a. surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656], 
bilateral oophorectomy) or; 
b. post-menopausal (defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative medical cause and FSH levels in the postmenopausal range for the laboratory involved) or; 
c. Abstinent* or; 
d. if engaged in sexual relations of child-bearing potential, agree to use 2 highly 
effective contraceptive methods (refer to  Section 6.3.1)  from the time of signing the 
informed consent form until at least [ADDRESS_907283] dose of Study Drug ( ISIS 
703802 or placebo)  
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception 
10. Males must be surgically sterile or, if engaged in sexual relations with a female of child -bearing potential, the subject must be using an acceptable contraceptive method 
(refer to  Section 6.3.1)  from the time of signing the informed consent form until at least 
[ADDRESS_907284] dose of ISIS 703802 
5.2 Exclusion Criteria  
1. Type 1 diabetes mellitus  
2. Active chronic liver disease, alcoholic liver disease, Wilson’s disease hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, genetic hemochromatosis, 
known or suspected hepatocellular carcinoma, history of or planned liver transplant for end-stage liver disease of any etiology  
3. Documented history of advanced liver fibrosis  
4. History of cirrhosis and/or hepatic decompensation including asc ites, hepatic 
encephalopathy, or variceal bleeding  
5. Uncontrolled hypertension (systolic > 160 or diastolic > 100 mm Hg) 
6. History of acute kidney injury within [ADDRESS_907285] unsuitable for inclusion, including the following: 
ISIS [ADDRESS_907286] (including trace) for blood on urinalysis.  In the event of a positive test, 
eligibility may be confirmed with urine microscopy showing ≤ 5 red blood cells per high power field 
b. Urine protein/creatinine ratio (UPCR) ≥ 0.25 mg/mg. In the event of a UPCR above this threshold, eligibility may be confirmed by a quantitative total urine protein measurement of ˂ 300 mg/24-hr 
c. Estimated GFR ˂ 60 mL/min/1.73 m
2 (as determined by [CONTACT_474263]- Epi[INVESTIGATOR_368010] (CKD -EPI) Equation)  
d. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > [ADDRESS_907287]  
e. Bilirubin > ULN, unless prior diagnosis and documentation of Gilbert’s syndrome in which case total bilirubin must be ≤ 3 mg/dL 
f. Alkaline phosphatase (ALP) > 1.[ADDRESS_907288]  
g. Platelet count ˂ LLN  
10. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B 
11. Uncontrolled hyper- or hypothyroidism. Subjects on dose stable replacement therapy for at least 3 months prior to Screening will be allowed  
12. History of clinically significant acute cardiac event within 6 months before Screening (includes stroke, transient ischemic attack, and coronary heart disease [angina pectoris, myocardial infarction, revascularization procedures])  
13. History of heart failure with NYHA greater than Class II  
14. Current acute or chronic inflammatory disease  
15. Hypersensitivity to the active substance or to any of the excipi[INVESTIGATOR_840] 
16. Active untreated mental disorder or depression. Subjects who are on a stable dose of medication (excluding atypi[INVESTIGATOR_16709] ) for at least 6 months before S creening and 
whose treating physicians consider them to be mentally stable may be enrolled  
17. Any major surgery including bariatric surgery within 3 months of S creening  
18. Weight change > 5% w ithin 3 months before Screening or during diet run in period 
19. Currently taking parenteral or chronic oral corticosteroids, amiodarone, tamoxifen, obeticholic acid, atypi[INVESTIGATOR_16709], HIV protease inhibitors, or ursodeoxycholic acid 
20. Alcohol consumption > 21 units of alcohol per week for men and > 14 units of alcohol per week for women over a two year time frame prior to the Baseline MRI eligibility (One drink "unit" or one standard drink is equivalent to a [ADDRESS_907289] liquor)  
21. Malignancy within [ADDRESS_907290]-
Treatment Follow -up Period, during which regular clinic al monitoring will be performed  
24. Use of Insulin or insulin analogs, GLP-1 agonists, and PPAR ᵞ agonists (pi[INVESTIGATOR_671556])  
25. Treatment with another investigational drug, biological agent, or device within 1 month 
of Screening, or 5 half-lives of investigational agent, whichever is longer 
26. Treatment with any non -Akcea/non -Ionis oligonucleotide (including small interfering 
ribonucleic acid [siRNA]) at any time or prior treatment with an Ionis oligonucleotide or siRNA within [ADDRESS_907291] previously received only 1 dose 
of an Ionis oligonucleotide as part of a clinical study may be included as long as ≥ [ADDRESS_907292] elapsed since dosing 
27. Blood donation of 50-499 mL within 30 days of Screening or of > [ADDRESS_907293] any metal implant (e.g., heart pacemaker, rods, screws, aneurysm clips)  that 
contraindicates MRI procedures.  
30. Have any other conditions, which, in the opi[INVESTIGATOR_671557], or could i nterfere with the subject participating 
in or completing the Study  
6. STUDY PROCEDURES  
6.[ADDRESS_907294] will be advised to maintain diet and exercise routines and remain on a stable regimen of diabetes and lipid medications (if they are already taking any).      
Subjects will undergo a medical history , including collection of race and ethnicity, physical 
examination including vital signs, 12-lead ECG, and have blood and urine samples taken for clinical laboratory testing. Subjects will be screened for HIV, hepatitis B, and hepatitis C . Safety 
labs may be retested  for determination of subject eligibility after consultation with the Sponsor 
Medical Monitor. 
ISIS [ADDRESS_907295] 4 weeks of diet 
run-in, followed by a qualification visit, during which final eligibility assessments will be 
performed. Subjects on stable diet known to the investigator and followed at the site may go 
from screening to qualificatio n without a 4-week diet run-in. At the qualification visit TGs will 
be measured . MRI will be obtained during screening once all other eligibility criteria are met to 
assess liver fat content.    
On confirmation of eligibility and prior to randomization, subjects  will also undergo a 24 hr 
urine collection for creatinine, albumin, and protein as a Qualification assessment.  
6.1.2 Treatment Period  
During the treatment period, eligible subjects  will be randomized and report to the S tudy Center 
for clinic visits. Subjects  will be randomized to 1 of 3 dose cohorts and receive 20 mg doses of 
Study Drug administered by [CONTACT_368128] (weekly) for 26 weeks in Cohort A, 40 mg doses of Study Drug administered by [CONTACT_671589] y 4 weeks for 21 weeks in 
Cohort B, and 80 mg doses of Study Drug administered by [CONTACT_213318] 4 weeks for 21 weeks in Cohort C ( Section 8.1).  
Collection and measurement of vi tal signs, physical examination results, ECGs, clinical 
laboratory parameters (Appendix B ), ISIS 70 3802 plasma concentrations, immunogenicity and 
biomarker samples, AEs and concomitant medication/procedure information will be perfor med 
according to the Schedule of Procedures in  Appendix A . 
Extensive Pharmacokinetic (PK) Subgroup Only: 
Within each cohort, a subgroup of approximately [ADDRESS_907296] blood samples for PK assessment (Appendix A  and C). 
6.1.[ADDRESS_907297] will be followed for safety assessments for 1 3 weeks after the Treatment Period 
(last dose through one dosing interval post last dose). During the post- treatment evaluation 
period, subjects will return to the Study Center for outpatient visits as outlined in  Appendix A  for 
safety and clinical laboratory evaluations.   
 
6.2 Study/Laboratory Assessments  
Laboratory analyte samples will be collected throughout the Study. A list of these analytes is contained in Appendix B .   
Blood chemistry and urine samples (excluding 24-hour urine collection) should be taken after fasting for [ADDRESS_907298] taken for safety reasons, may be taken at any 
time, irrespective of fasting status.  During this time subjects  can drink water and should ensure 
that they consume sufficient water to not become dehydrated . 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
42 If tests are uninterpretable (e.g. , due to clumpi[INVESTIGATOR_007], hemolysis or quantity not sufficient) or 
missing, a repeat blood or urine specimen should be re-drawn as soon as possible (ideally within 
1 week ). 
While on treatment hematology  samples will be collected every 14 days  +/- 2 days. E ach time a 
hematology lab is drawn and sent to the central laboratory for analysis, an additional sample 
should be collected in parallel and analyzed locally . In the event that both the central and local 
sample s are unreportable (e.g., due to hemolyzed or clumped blood samples), subject  dosing 
cannot continue until another sample is repeated and determined not to have met a platelet 
stoppi[INVESTIGATOR_1877]. 
If there is no reportable platelet count within [ADDRESS_907299]  to hold dosing until a new platelet count is obtained and reviewed. 
While on treatment, blood samples for liver function testing will be collected every 14 days  
+/- [ADDRESS_907300] 3 months of the study 
treatment, and monthly thereafter during the Treatment Period per  Section 8.5.1.   
While on treatment, blood and urine samples for renal function testing will be collected every 
14 days +/- [ADDRESS_907301] ion 8.5.2.   
All lab samples are to be sent to the central laboratory by [CONTACT_474275]. Lab 
Alerts issued as per protocol safety monitoring requirements or stoppi[INVESTIGATOR_671558], the Sponsor and the CRO Medical Monitors, the Sponsor Drug Safety Physician, and the Clinical Trial Manager (CTM), and should be received by [CONTACT_77314] 2 days from sample collec tion. Hematology results from the site’s local laboratories are received 
by [CONTACT_671590] s' standard reporting time and should be entered 
as soon as possible into the eCRF to inform the Sponsor and CRO study monitoring teams.  
All platelet count results must be reviewed promptly (within 4 8 hours of receipt) by [CONTACT_3786], or designee, to ensure that the count has not met the stoppi[INVESTIGATOR_671559] 75,000/mm
3 as specified in  Section 8.6.3.  Any case of a platelet count 
reduction to levels below 50,000/mm3 is considered an adverse event of special inter est and must 
be reported in an expedited fashion to the Sponsor as per  Sections  9.3.[ADDRESS_907302] also be reviewed promptly (within 48 hours of receipt) by [CONTACT_737], or designee, to ensure that the result has not met the stoppi[INVESTIGATOR_1877]. Any event meeting renal stoppi[INVESTIGATOR_474253] 8.6.[ADDRESS_907303] be reported in an expedited fashion to the Sponsor as per  Sections  9.3.3  
and 9.4.1. 
All lab alerts received, including those related to plate let, liver, or renal function 
monitoring/stoppi[INVESTIGATOR_004], are also reviewed promptly by [CONTACT_213323]. Within 24 hours of receiving an actionable lab 
alert the CRO Medical Monitor will communicate instructions to the Investigator and the study 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
43 personnel by e mailing them the Safety Surveillance Form that needs to be signed by [CONTACT_3786]/study personnel and promptly returned to the Sponsor and CRO Medical Monitor.  
In urgent cases, such as platelet  results below 50,000/mm3, or liver or renal test results reaching a 
critical stoppi[INVESTIGATOR_671560].  
Further information on safety monitoring and actions to be taken by [CONTACT_368159] 8.5.3 and 8.6.3. 
6.2.1 Physical Exams and Vital Signs 
Physical exams and vital signs will be performed as indicated in the Schedule of Procedures 
(Appendix A ). Vital signs should include weight, blood pressure (BP), pulse rate, respi[INVESTIGATOR_287677].  BP and pulse rate will be recorded after the subject  has been in a sitting 
position for at least 5 minutes. BP should always be measured on the sam e arm (preferentially on 
the left arm).  Height will be measured at Screening.  
6.2.2 Electrocardiography  
Electrocardiography (ECG) will be conducted at Screening, Day 1, (prior to the first dose of 
Study Drug), and again during the treatment period as follows per dosing cohort: 
• Cohort A at Weeks 5, 13, 21, and 27/ET  
• Cohorts B and C at Weeks 5, 13, 21 and 25/ET 
In all cohorts, ECGs will be conducted during the post- treatment follow-up period at scheduled 
visits . 
ECGs will be recorded after the subject  has been resting in a supi[INVESTIGATOR_21683] 
[ADDRESS_907304] blood samples for PK assessment (Appendix C ). 
6.[ADDRESS_907305] refrain from sperm/egg donation 
and either be abstinent
† or practice effective contraception from the time of signing the informed 
consent form until at least a period of [ADDRESS_907306]’s last dose of study treatment.  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
44 For the purposes of this study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet one of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male subject s: 
• Effective male contraception includes a vasectomy with negative semen  analysis at 
follow-up, or the use of condoms together with spermicidal 
foam/gel/film/cream/suppository  
• Male subjects with partners that are pregnant must use condoms as contraception to 
ensure that the fetus i s not exposed to the Study Drug 
For female subjects and female partners of male subjects : 
• Using 2 of the following acceptable methods of contraception:  surgical sterilization (e.g., 
bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or any 2 barrier methods (a combination of male or female condom * with  diaphragm, sponge, or 
cervical cap)  together with spermicidal foam/gel/film/cream/suppository  
†Note:  Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the subject . Periodic abstinence (e.g., calendar, ovulation, 
symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception.  
*Note:  A female condom and a male condom should not be used together as friction 
between the two ca n result in either or both products failing.  
6.3.[ADDRESS_907307]  10 hours before visits requiring fasted blood 
sampling.   
7. S TUDY DRUG  
7.1 Study Drug Description  
Study Drug ( ISIS 703802 or Placebo)  characteristics are listed in  Table 1. 
Study Drug ( ISIS 703802 or Placebo)  will be provided as 0.[ADDRESS_907308] be stored between 2 to 8 °Celsiu s and be protected from light. 
7.1.1 ISIS 703802 ( ISIS  703802)  
ISIS 703802  vials contain 100 mg/mL ISIS 703802  in water  for injection .  Additionally, sodium 
phosphate buffer and sodium chloride are added to control the measure of the acidity or basicity 
of the solution (pH) and tonicity, respectively.  The target pH is 7.4. 
7.1.2 Placebo   
Placebo vials contain 0.9% sodium chloride in wa ter for injection .  1.6 µg/mL riboflavin is add ed 
to ensure color matching of placebo vials to ISIS 703802 vials . 
Table 1 Study Drug Characteristics  
Study Drug  ISIS 703802  Placebo  
Strength 100 mg/ mL  Not Applicable   
Volume/Formulation  0.8 mL/  per 2.0 mL  vial 0.8 mL/ per 2.0 mL vial  
Route of Administration  SC* SC* 
                       * SC = subcutaneous  
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged Study Drug ( ISIS 703802 or placebo) 
labeled in accordance with specific country regulatory requirements.  
7.3 Study Drug Accountability  
The study staff is required to document the receipt, dispensing, and return of Study Drug ( ISIS 
703802 or placebo)  supplies provided by [CONTACT_1034]. The subject  must return all used and 
unused Study Drug to the Study Center for accountability. The Study Ce nter must return all used 
and unused Study Drug to the Sponsor or designee. All used syringes must be disposed of as per the site’s hazardous waste destruction  policy. 
8. T REATMENT OF SUBJECTS  
8.1 Study  Drug Administration 
Study Drug ( ISIS 703802 or placeb o) will be administered to subjects  by [CONTACT_671591]: 
Cohort A: a single SC dose of 20 mg  every week (weekly) for 26 weeks  and 26 doses 
Cohort B: a single SC dose of 40 mg once every 4 weeks for 21 weeks and 6 doses 
Cohort C: a single SC dose of [ADDRESS_907309]  and/or 
caregiver.  
Subjects  in Cohort A receive [ADDRESS_907310] 2  days apart.  
Every effort should be made to ensure the previous dose is given 7 days prior to a scheduled 
clinic visit.  
Volumes to be administered are shown in Table 2 . Please refer to the Study Drug Manual 
provided by [CONTACT_474280] (ISIS 703802 or placebo) preparation and administration. 
Table 2 Study Drug  Dosing Information 
Cohort  Treatment  Volume to Administer/Dose  # Doses  Total Study Drug  
A 20 mg ISIS 703802 
or placebo  
(Every week) 0.2 mL  26 520 mg  
B 40 mg ISIS 703802 
or placebo  
(Every 4 weeks)  0.4 mL  6 240 mg  
C 80 mg  ISIS 703802 
or placebo  
(Every 4 weeks)  0.8 mL  6 480 mg  
8.2 Other Protocol -Required Drugs  
No other Study Drug treatments are required by [CONTACT_760].  
8.3 Other Protocol -Required Treatment Procedures  
There are no other treatment procedures required by [CONTACT_671592] . 
8.4 Treatment Precautions  
No specific treatment precautions are required.  
8.5 Safety Monitoring Rules 
Please refer also to the “Guidance for Investigator ” section of the Investigator’s Brochure. 
For the purposes of safety monitoring, Baseline is defined as  the average of the pre- dose test 
closest to Day [ADDRESS_907311] be initiated based on the more critical (lower or higher, as 
relevant) of the 2 values.  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
47 Confirmation Guidance :  At any time during the study (treatment or post-t reatment follow-up 
periods), the clinical laboratory results meeting any of the safety monitoring criteria presented 
below must be confirmed by [CONTACT_10533] (ideally in the same laboratory that 
performed the initial measurement) on new specimens prior to administer ing the next dose of 
Study Drug  (ISIS 703802  or placebo).  All new specimen collections should take place as soon as 
possible (ideally within 3 days of the initial collection) .  
In addition, as described in  Section 6.2 hematology labs should be sent in parallel to the central 
and local laboratory for analysis. 
Stoppi[INVESTIGATOR_86556]: The Investigator may interrupt or permanently discontinue study 
treatment for any medical reason including changes in clinic al laboratory results.   
In the event of an initial clinical laboratory result that meets a stoppi[INVESTIGATOR_107160], subjects must 
not be re-dosed until a confirmatory test result has been reviewed by [CONTACT_10542]. If any of the stoppi[INVESTIGATOR_3418] d escribed below are met and are confirmed, the subject will be 
permanently discontinued from further treatment with Study Drug (
ISIS 703802  or placebo), 
evaluated fully as outlined below and in consultation with the Study Medical Monitor or appropriately qualified designee, and will be entered into the post-treatment evaluation portion of the study. In general, subjects  who do not meet the stoppi[INVESTIGATOR_671561]. However, the Investigator and the Study Medical Monitor (or approp riately 
qualified designee) should confer as to whether additional close monitoring of the subject is 
appropriate. 
Additional Guidance: If possible, a PK sample should be collected as soon as possible after a 
SAE has occurred (preferably within 2 weeks). In addition, if a subject is asked to return to the 
clinic for additional evaluations due to an AE, then a PK sample should be taken at the time of the unscheduled visit. 
8.5.1 Safety Monitoring Rules for Liver Chemistry Tests  
The following rules are adapted from the FDA guidance for industry, “Drug- Induced Liver 
Injury:  Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S .  Department of Health and Human 
Services, Food and Drug Administration, July [ADDRESS_907312] 3 -months of the study treatment period, and monthly thereafter.  Upon completion of the 
study treatment period, liver chemistry tests  should be monitored per visit schedule in 
Appendix A . 
In the event of appearance of symptoms or signs of hepatic injury (jaundice, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, abnormal bleeding or bruising, or eosinophi lia > ULN ) liver enzymes and bilirubin should be tested as soon as possible. Testing at 
a lab that is local to the subject  is permissible for this purpose. 
In the event of an ALT or AST measurement that is > [ADDRESS_907313] (or the greater of [ADDRESS_907314] if the Baseline value was > ULN) at any time during the study ( treatment or 
post-t reatment period), the initial measurement(s) should be confirmed. 
ISIS [ADDRESS_907315] levels > [ADDRESS_907316] their liver chemistry tests 
(ALT, AST, ALP, international normalized ratio [ INR] and total bi lirubin) retested at least 
once-weekly until ALT and AST levels become ≤ [ADDRESS_907317] be reviewed promptly (within 48 hours of receipt) by [CONTACT_368162][INVESTIGATOR_1877] s. 
Further Investigation into Liver Chemistry Elevations : For subjects  with confirmed ALT or AST 
levels > [ADDRESS_907318] , the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history of  exposure to environmental chemical agents and travel 
4. Serology for viral hepatitis (hepatitis A virus  [HAV] immunoglobulin M [ IgM], hepatitis 
B surface antigen [ HBsAg ], hepatitis C virus [ HCV ] antibody, Cytomegalovirus [ CMV ] 
IgM, and EBV antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consultations, hepatic CT or MRI scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical Monitor. Repetition of the above evaluations should be considered if a subject ’s ALT and/or AST levels reach [ADDRESS_907319] be promptly (within 48  hours of receipt) 
reviewed by [CONTACT_368094]. 
Lab alerts for abnormal liver chemistry tests will be issued for:  1) ALT or AST > [ADDRESS_907320]; 
2) ALT or AST > 2 x Baseline; 3) total bilirubin > ULN; 4) ALP > 1.5x ULN. These alert levels 
are set to anticipate the risk of a combined elevation of aminotransferases and bilirubin as per the FDA Guidance.  
8.5.[ADDRESS_907321] 3  months of the study treatment period, and monthly thereafter. Upon completion of the 
study treatment period, urine renal biomarkers should be monitored as per visit schedule in Appendix A . 
In the event of appearance of symptoms or signs consistent with renal dysfunction such as hematuria, polyuria, anuria, flank pain, new-onset hypertension, nausea and/or anorexia, renal function should be tested as soon as possible. Testing at a lab that is local to the subject is 
permissible for this purpose. 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
49 While on treatment during the course of the study, urinary surveillance may include urinalysis to 
include urine albumin/creatinine ratio (UACR), urine protein/creatinine ratio (UPCR) and urinary red blood cells (RBCs), as well as serum creatinine and cystatin -C, which will be 
monito red every [ADDRESS_907322] 3-months of the study treatment period, and monthly 
thereafter. In addition, other biomarkers of acute renal injury may also be measured if a safety signal is seen that warrants further testing (Appendix B ).  
The assessment of serum creatinine, cystatin -C, and urinalysis more frequently than per the 
Schedule of Procedures in Appendix A , will be guided by [CONTACT_671593]. 
Any decision taken by [CONTACT_671594]. In addition, the decision to discontinue Study Drug may also be based on lesser changes in these parameters observed in isolation or association with 
other renal -related abnormalities. Any decision taken to restart study medication will be made in 
consultation with the Study Medical Monitor taking into account all a vailable and relevant data.  
All results of renal function tests  must be reviewed promptly (within 48 hours of receipt) by [CONTACT_368162][INVESTIGATOR_1877] s. 
Lab alerts for abn ormal renal tests will be issued for: Estimated GFR  (eGFR)  (by [CONTACT_9289] -EPI 
[INVESTIGATOR_14420]) decrease from Baseline > 25%, urine albumin/creatinine  ratio  (UACR)  > 165 mg/g, 
urine protein/creatinine ratio (UPCR)  > 325mg/g , or an increase in s erum cr eatinine from 
Baseline > 0.3 mg/dL , or new onset hematuria defined as ≥5 RBC/hpf (except for menstruating 
females ). 
These alert levels are set to anticipate and prevent the risk of a medically significant change in renal function while receiving Study Drug. 
Abnormal test results should be repeated. In the event of a confirmed  laboratory result meeting 
one or more of the above criteria , the following supplemental renal tests should be obtained 
within 7 days, and additional laboratory studies may be performed to identify if other potential 
etiologies may be a causal factor :  
Serum creatinine, urine culture, urine microscopy sample with inspection of sediment. 
The Investig ator should also review the subject ’s concomitant medications for potentially 
nephrotoxic agents, and, with the results of these evaluations, review any decision to continue or discontinue the subject in consultation with the Study Medical Monitor. 
8.5.[ADDRESS_907323] dose (as per visit schedule).  
All platelet count results must be reviewed promptly (within 48 hours of re ceipt) by [CONTACT_368167][INVESTIGATOR_671562] [ADDRESS_907324]  could be approaching the 
dose interruption rule of 75,000/mm3.   
Any case of a platelet count reduction to levels below 50,000/mm3  is considered an adverse 
event of special interest and should be reported in an expedited fashion to the Sponsor. In this 
case, the Investigator should refer the subject to a hematologist to provide diagnos tic and 
therapeutic management.  
Lab alerts related to platelet monitoring/stoppi[INVESTIGATOR_368027]:  1) platelet counts are < 140,000 mm
3, 2) platelet count is ≥ 30% decreased from Baseline, or 3) the hematology 
sample is unreportable. All lab alerts  are reviewed promptly by [CONTACT_1689], and 
instructions are communicated to the Investigator and the study personnel within 24 hours of receiving an actionable lab alert.  
Actions to be taken in the event of reduced platelet count are shown in Table 3 . 
In the event of a platelet count ˂ 100,000/mm
3, the laboratory tests outlined in Table 3 should be 
performed as soon as possible. In addition to action taken as outlined in Table 3, in the event of a 
platelet count <100,000/mm3, tests outlined in Appendix E  should be performed as soon as 
possible. Additional lab tests , if warranted,  will be deter mined by [CONTACT_671595].  
8.5.4 Safety Monitoring for Bleeding Events 
Subjects will be evaluated for occurrence of bleeding events continuously after the start of Study 
Drug treatment (Day 1)  up to the end of the follow-up period for all cohorts. All bleeding events 
are considered adverse events and reported on adverse event case report form.      
Bleeding events that are either major or clinically -relevant non -major bleeding (as defined 
below) will need to be monitored and treated immediately. Subjects with a suspected bleeding event will undergo additional testing if deemed appropriate by [CONTACT_474285] (S)AE case report form will be completed. In addition, if bleeding is considered significant, hemoglobin (Hb), hematocrit (HCT), aPTT, PT, INR, and platelet count are to be obtained. In addition, approximately [ADDRESS_907325] be stored allowing for a centralized assessm ent of ISIS 703802
 concentrations.  
In addition, if a minor bleeding event occurs, the Investigator should notify the Sponsor Medical Monitor (or designee) and additional testing of coagulation parameters (aPTT, prothrombin time [PT], INR), platelet count, and platelet volume may be performed.  
Definitions :  
Major bleeding (MB) is defined as one of the following ( Büller et al. 2007
):  
1. Fatal bleeding  
2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspi[INVESTIGATOR_1304], intraocular, retroperitoneal, intraarticular if in a major joint, or pericardial, or intramuscular with compartment syndrome  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
51 3. Clinically overt bleeding leading to transfus ion of ≥ 2 units of packed red blood cells or 
whole blood or a fall in hemoglobin of 20 g/L (1.24 mmol/L) or more within [ADDRESS_907326] (Büller et al. 2007).  
Minor bleeding events are those that do not fulfill the criteria for major bleeding or 
clinically -relevant, non-major bleeding events (defined above), for example, excess bruising, 
petechiae, gingival bleeding on brushing teeth.  
8.5.[ADDRESS_907327] Self Monitored Blood Glucose (SMBG) levels 
weekly and report back alert values to the site. Subjects  will be instructed to promptly report 
symptoms of hypoglycemia: headache, heart pounding, confusion, disorientation, numbness or 
tingling, pale skin, shakiness or tremulousness, increased appetite, anxiousness or nervousness, lightheadedness or dizziness, sweating and , weakness. If subjects  suspect they might be having a 
hypoglycemia reaction, they should check their blood glucose using their meters as soon as possible, before treatment if possible, provided they feel it is safe to do so. If there is doubt about safety they should treat the event first, using some sugar, milk, or juice for example, then obtain and record a blood glucose value as soon as possible thereafter. The time and nature of treatment should be noted, and especially if any blood glucose result was before or after treatment.  If a 
subject  presents with symptoms of hypoglycemia, the Inv estigator will need to take  immediate 
action to confirm the subject ’s glucose level and treat the subject  accordingly.  Severe 
hypoglycemia will be qualified as a SAE only if it fulfills SAE criteria.  
Classification of Hypoglycemia 
The alert value for hypog lycemia  is ≤ 70 mg/dL (≤ 3.9 mmol/L) blood glucose  concentration . 
Severe Hypoglycemia  
Requires assistance of another person to actively administer carbohydrates, glucagon, or take 
other corrective actions. Glucose concentrations may not be available during an event.  
Neurological recovery following glucose levels returning to normal considered sufficient evidence that event was induced by [CONTACT_671596]. 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
52 Documented Symptomatic Hypoglycemia  
Typi[INVESTIGATOR_671563] ≤ 70 mg/dL 
(≤ 3.9 mmol/L) .  
Asymptomatic Hypoglycemia  
Not accompanied by [CONTACT_11017][INVESTIGATOR_671564] 
≤ 70 mg/dL (≤ 3.9 mmol/L). 
Probable Symptomatic Hypoglycemia Typi[INVESTIGATOR_671565] ≤ 70 mg/dL (≤ 3.9 mmol/L). 
A documented severe hypoglycemic event is defined as one in which the subject  requires the 
assistance of another person to obtain treatment for the event and has a blood glucose level 
≤ 70 mg/dL (≤  3.9 mmol/L). The rescue treatment of hypoglycemia may include IV glucose or  
buccal or intramuscular glucagon. 
The definition of severe symptomatic hypoglycemia includes all epi[INVESTIGATOR_37473]-treatment and which were thus thought to place subjects  at risk for injury to themselves or others. 
8.5.[ADDRESS_907328] the Investigator and a 
central laboratory FPG measurement will be performed).  
The threshold values are defined as follows, depending on study period: 
From Baseline visit to Week 13 (including value at Week 13) of Randomized Treatment period: 
• Blood Glucose > 270 mg/dL (15.0 mmol /L) 
From Week [ADDRESS_907329]- treatment Follow -up (Week 4, [ADDRESS_907330] end of treatment period): 
• Blood Glucose > 240 mg/dL (13.3 mmol/L) or 
• HbA1c > 9% (for subjects with Baseline HbA1c < 8%) and HbA1c increase of more than 
1% from Baseline (for subjects with Baseline HbA1c ≥ 8%) 
In case of blood glucose/HbA1c above the threshold values, the Investigator should ensure that 
no reasonable explanation exists for insufficient glucose control and in particular that: 
• Blood glucose was actually measured in the fasting condition 
• Absence of intercurrent disease which may jeopardize glycemic control. In case of an 
emergency such as unplanned hospi[INVESTIGATOR_059] (e.g., surgery, infection), the Investigator 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
53 can take appropriate measures for glycemic control. If the measure does not exceed 
7 days, then it will not be considered a rescue. If the measure lasts beyond 7 days then it will be treated as a rescue 
• Compliance to treatment is appropriate  
• Compliance to diet and lifestyle is appropriate 
If any of the above can reason ably explain the insufficient glycemic control, the Investigator 
should undertake appropriate action, i.e.: 
• Investigation and treatment of intercurrent disease (to be reported in AE/concomitant medication parts of the eCRF) 
• Stress on the absolute need to be compliant to treatment 
• Organize a specific interview with a Registered Dietician or other qualified nutrition professional and stress on the absolute need to be compliant to diet and lifestyle recommendations 
• Schedule an  FPG/HbA1c assessment at the next visit 
If none from the above-mentioned reason can be found, or if appropriate action fails to decrease blood glucose/HbA1c under the threshold values, rescue medication may be introduced at the Investigator discretion and according to local guidelines. 
All assessments for primary and secondary efficacy and safety parameters planned in final  
primary endpoint assessment visit should be performed before adding the rescue medication if 
possible. Then the subject continues the study treatment and stays in the st udy in order to collect 
safety  information. The planned visits and assessments should occur until the last scheduled 
visit.  (See more details in  Appendix A ). 
Note: After Study Drug discontinuation any treatments are permitted, as de emed necessary by  
[CONTACT_737].  
8.[ADDRESS_907331]  with Study Drug will be stopped permanently: 
1. ALT or AST > [ADDRESS_907332] >  [ADDRESS_907333] , which is confirmed and persists for ≥ [ADDRESS_907334] >  [ADDRESS_907335] (or the greater of [ADDRESS_907336] if the Baseline 
value was > ULN), which is confirmed and total bilirubin >  [ADDRESS_907337]  or INR > 1.[ADDRESS_907338] >  [ADDRESS_907339]  (or the greater of [ADDRESS_907340] if the Baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
54 pain or tenderness, fever, rash, or eosinophi lia (> ULN ) felt by [CONTACT_37854]/injury   
8.6.[ADDRESS_907341] Results   
In the event of an eGFR (by [CONTACT_9289] -EPI [INVESTIGATOR_14420]) meeting any of the following criteria, or any 
change in renal biomarkers deemed by [CONTACT_671597], a serum 
creatinine, urine culture,  and urine microscopy sample with inspection of sediment should be 
immediately obtained . 
Dosing of a subject  with Study Drug ( ISIS 703802 or placebo) will be stopped permanently  if 
testing in  any of the following values is con firmed in the absence of an alternative explanation : 
1. eGFR (CKD -EPI) decrease of > 25% from Baseline  
2. eGFR (CKD -EPI) value < 45 mL/min/1.73 m2 
3. UACR >165mg/g  
4. UPCR >325mg/g 
5. New onset of hematuria  (defined as ≥5 RBC/hpf) 
Irrespective of whether the stoppi[INVESTIGATOR_10455], the follow-up schedule and 
frequency of renal function monitoring after the initial event will be determined by [CONTACT_144369]. The Investigator should consider consulting a local nephrolog ist for any change of renal function that presents a concern.  If a 
renal biopsy is performed, a sample specimen should be made available for examination by [CONTACT_474287].   
8.6.3 Stoppi[INVESTIGATOR_213276] a low platelet count are summarized in Table 3  below. 
In the event of any platelet count < 50,000/mm
3, or a platelet count less than 75,000/mm3 that 
occurs while the subject is already on reduced dose, dosing of the subject  with Study Drug will 
be stopped permanently (Table 3).  Platelet count will be monitored daily until 2 successive 
values show improvement then monitored every 2- 3 days until platelet count is stable.  
Administration of steroids is recommended for subjects  whose platelet count is less than 
25,000/mm3.  Recovery in platelet count may be accelerated by [CONTACT_37856].  Treatment guidelines for immune thrombocytopenia ( Provan et al. 2010)  recommend 
Dexamethasone 40 mg daily for 4 days every 2 -4 weeks for 1 -4 cycles; Prednis(ol)one 
0.5-2 mg/kg/d for 2 -4 weeks then taper; or methylprednisolone 30 mg/kg/day for 7 days  
(note:   may require continuation with oral steroids after methylprednisolone ). 
In the event of a platelet count ˂ 75,000/mm3 and ≥ 50,000/mm3, dosing of a subject  with Study 
Drug  should be suspended temporarily until the platelet count has recovered to ≥ 100,000/mm3.  
If dosing is continued, it must be at a reduced dos e as shown in Table 3. The suitability of the 
subject  for continued dosing will be determined by [CONTACT_671598]’s  platelet count, whether any bleeding events were experienced by [CONTACT_423] , and the 
speed of recovery of platelet count after interruption  of dosing. 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
55 If, after reintroduction of Study Drug, the platelet count again falls below 75,000/mm3, then 
dosing of the subject with Study Drug  will be stopped permanently.  
Once a subject commences weekly monitoring, this frequency of monitoring should continue 
until the platelet count returns to the normal range ( ≥140,000/mm3) for [ADDRESS_907342] met a 
stoppi[INVESTIGATOR_10450]. 
 
  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
56 Table 3 Actions in Subjects  with Low Platelet Count 
Platelet Count on Rx  Drug Dose  Monitoring  
Normal range, ≥ 140K/mm3 No action  Monitor every 14 days (+/ - 2 days)  
≥100K  to <140K/mm3 No action  Closer observation  
Monitor every week *  
≥75K to <100K/mm3 Permanently reduce the dose by 50 % as 
follows:  
For Cohort A:  reduce to 1 0 mg every 
week   
For Cohort B:  reduce to 20 mg every 4 
weeks  
For Cohort C:  reduce to 40 mg every 4 
weeks  Closer observation  
Monitor every week * 
≥50K to <75K/mm3 Pause dosing  
When platelet count returns to 
> 100K/mm3 restart dosing as follows 
only if approved by [CONTACT_671599] : 
For Cohort A:  reduce to 1 0 mg every 
week  
For Cohort B:  reduce to 20 mg every 4 
weeks  
For Cohort C:  reduce to 40 mg every 4 
weeks  
or 
Permanently discontinue Study Drug if it 
occurs while on already reduced dose  Closer observation  
Monitor every 2-3 days until 2 successive 
values show improvement  
Consider discontinuation of antiplatelet agents/non-steroidal anti -inflammatory 
drug (NSAIDS)/ anticoagulant medication  
≥25K to <50K/mm3 Permanently discontinue Study Drug   Closer observation: 
Monitor daily until 2 successive values 
show improvement then monitor every 2-
3 days until platelet count stable  
Discontinue antiplatelet agents/NSAIDS/anticoagulant medication 
while platelet count ˂ 50K/mm
[ADDRESS_907343] to provide diagnostic and therapeutic management  
˂ 25K/mm3 Permanently discontinue Study Drug  Closer observation:  
Monitor daily until 2 successive values 
show improvement then monitor every 2-
3 days until platelet count stable  
Steroids recommended**  
Consider need for hospi[INVESTIGATOR_474250]/NSAIDS/anticoagulant medication while platelet count ˂ 50K/mm
[ADDRESS_907344] to provide diagnostic and therapeutic management  
* Once a subject commences weekly monitoring this frequency of monitoring should continue until the platelet count returns to 
the normal range (≥ 140,000/mm3) for 2 successive values . 
** Recovery in platelet count may be accelerated by [CONTACT_37711].  Treatment guidelines for immune 
thrombocytopenia (Provan et al. 2010)  recommend Dexamethasone 40 mg daily for 4 days every 24 weeks for 1- 4 cycles; 
Prednis(ol -)one 0.5- 2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 30 mg/kg/day for 7 days (note:  may require 
continuation with oral steroids after methylprednisolone).  
ISIS [ADDRESS_907345]  with Study Drug will be stopped 
permanently.  
Dose adjustments, including dose interruptions, and/or decreasing the dose or dose frequency 
will be allowed for safety and tolerability. Any proposed adjustments to treatment 
schedule must be discussed with, and approved by, the Study Medical monitor prior to initiation.  
8.7 Adjustment of Dose and/or Treatment Schedule  
Dose frequency adjustments for platelet count reduction mus t be made in accordance with 
Section 8.6.3 and Table 3  (above). 
Other dose adjustments, including dose interruptions, and/or decreasing the dose will be allowed for safety or tolerability in  consultation with the Sponsor Medical Monitor.   
Subjects  may have their dose interrupted in response to AEs, and the Study Medic al Monito r will 
be informed. 
8.8 Discontinuation of Study Drug/Treatment  
A subject must permanently discontinue study treatment for any of the following: 
• The subject becomes pregnant. Report the pregnancy according to instructions in 
Section  9.5.4 
• The subject withdraws consent 
• The subject experiences an adverse event (AE) that necessitates permanent discontinuation of Study Drug 
• The subject develops laboratory test abnormalities that meet any of the stoppi[INVESTIGATOR_671566] 8.6.1 t o 8.6.3 
• When a platelet count  of less than 50,000/mm
3, or a platelet count less than 75,000/mm3 
while the patient  is on a reduced dose. 
The reason for discontinuation of Study Drug Treatment must be recorded in the electronic Case Report Form (eCRF) and source documentation. 
Subjects who discontinue treatment early should be entered into the post- treatment evaluation 
period.  Every effort should be made to complete the early termination study procedures and 
observations at the time of withdrawal (see  Appendix A ). 
If a subject discontinues treatment a fter only [ADDRESS_907346] 6 weeks after discontinuing Study Drug and then at 8 (weekly dosing cohort) or 10 (every 4 week dosing cohorts) and [ADDRESS_907347] end of treatment period (as per visit schedule).   
If the subject  declines or is unable to participate in the above, the early termination visit 
procedures should be performed at the time of withdrawal, at a minimum, and ideally within 
[ADDRESS_907348] be withdrawn from the Study for any of the following: 
• Withdrawal of consent 
• The subject is unwilling or unable to comply with the protocol 
• The subject  meets any of the Exclusion Criteria (see Section 5.2)  after enrolling in the 
study that in the opi[INVESTIGATOR_213280] a safety risk to the subject  
Other reasons for withdrawal of subjects from the Study might include: 
• At the discretion of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal. All information, including the reason for withdrawal from Study, must be recorded in the eCRF.  
Any subject who withdraws consent to pa rticipate in the Study will be removed from further 
treatment and study observation immediately upon the date of request. These subjects should be encouraged to complete the early termination study procedures and observations at the time of withdrawal (Appendix A ).   
For subjects  withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  early ter mination (ET) study procedures and observations at the time of 
withdrawal  (see Appendix A ).  
8.[ADDRESS_907349]’s  
eCRF . Adverse event s related to administration of these therapi[INVESTIGATOR_10459] . 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
59 8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter (OTC) medications, herbal medications and vitamin supplements) administered between Screening and the end of the post- treatment evaluation period . All concomitant 
medications/treatments and significant non -drug therapi[INVESTIGATOR_014] (including supplements and assistive 
devices) received by a subject, including changes in the subject’s current medications, must be recorded in the subject’s source documents and CRF. Subjects taking over the counter omega-3 fatty acids should make every effort to remain on the same brand throughout the study. 
[IP_ADDRESS] Allowed Concomitant Therapy 
Ibuprofen may be used for symptomatic pain relief. Any other therapy  for pain  (including OTC 
medications  such as acetaminophen ) should be approved by [CONTACT_671600].  
Any medications deemed necessary by [CONTACT_671601],  except those listed in the disallowed concomitant therapy.  In such cases, 
the Investigator must consult the Sponsor Medical Monitor to decide on subject continuation or 
withdrawal from the study. 
[IP_ADDRESS] Disallowed Concomitant Therapy 
The use of prescription and OTC medications including nonsteroidal anti- inflammatory drugs 
(with the exception of occasional ibuprofen) is prohibited during this study unless the occurrence 
of an AE requires a drug therapy. In cases  when there is no AE , the Investigator must consult the 
Sponsor Medical Monitor to decide on subject continuation or withdrawal from the study. 
The medications and therapy  identified in exclusion criteria,  Section 5.2 are also d isallowed 
concomitant medications and are prohibited during the course of study, unless there is a safety 
concern. In those cases, the Medical Monitor needs to be notified and rationale provided by [CONTACT_737]. 
Concomitant therapy with oral corticosteroids used as re placement therapy for pi[INVESTIGATOR_671567] (e.g., Pulmicort®), or intra -articular, or topi[INVESTIGATOR_671568]; however,  the subject must be on a stable regimen for at  least [ADDRESS_907350]  should consult with the Site Investigator or designee prior to initiating any new 
medication, in cluding non-prescription or herbal compounds or any other non- drug therapy.  
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement , bacterial cultures) performed between  
Screening and the end of the post- treatment evaluation period . 
8.11 Treatment Compliance  
Compliance with treatment dosing is to be monitored and recorded by [CONTACT_37714].  The 
Study Center staff is required to document the receipt, dispensing, and return/destruction  of 
ISIS [ADDRESS_907351] of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor  or designee is responsible for regulatory submissions and reporting to the 
Investigators of serious adverse events (SAEs) including suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) per the International Conference on Harmonization (ICH) guidelines E2A and ICH E6. Country-specific regulatory requirements will be followed in accordance with local country regulations and guidelines. 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations. The Data and Safety Monitoring Board ( DSMB ) will 
be notified of any SAE as specified in the DSMB  charter.  
In addition to the Investigator’s assessment of relatedness, the Sponsor  or designee  will evaluate 
the available information and perform an independent assessment of relatedness. While the Sponsor may upgrade an Investigator’s decision, it is not permissible to downgrade the Investigator’s opi[INVESTIGATOR_37567] a S[LOCATION_003]R.  
Appropriate personnel at the Sponsor  or designee will unblind S[LOCATION_003]Rs for the purpose of 
regulatory reporting. The Sponsor  or designee will submit S[LOCATION_003]Rs to Regulatory Agencies in 
blinded or unblinded fashion according to local regulation . The Sponsor or designee  will submit 
S[LOCATION_003]Rs to Investigators in a blinded fashion. 
For the purpose of regulatory reporting of S[LOCATION_003]Rs, there are no “expected” AEs  in this study 
population.  For Study Drug (ISIS 703802 or placebo) “expected” AEs , refer to the Investigator ’s 
Brochure.  
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign ( including a clinically significant 
abnormal laboratory finding, for example ), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
61 9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any AE caused by [CONTACT_81807] . 
A suspected adverse reaction  is any AE for which there is a reasonable possibility that the drug 
caused the adverse event. A suspected adverse reaction implies a lesser degree of certainty about 
causality than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A serious adverse event is any adverse event  that in the view of either the Investigator or 
Sponsor, meets any of the following criteria:  
• Results in death  
• Is life threatening: that is, poses an immediate risk of death at the time of the event  
An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of 
either the Investigator or Sponsor, its occurrence places the subject at immediate risk of 
death. It does not include an AE  or suspected adverse reaction that, ha d it occurred in a 
more severe form, might have caused death 
• Requires inpatient hospi[INVESTIGATOR_10461] 24 hours to a medical facility and does not always qualify as an AE  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in a congenital anomaly or birth defect in the offspring of the subject (whether 
the subject  is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospi[INVESTIGATOR_671569], based upon appropriate 
medical judgment, they may jeopardize the subject and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059] , or the development of drug dependency or drug abuse 
9.4 Monitoring and Recording of Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a subject prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as AEs unless the pre-existing condition worsened. The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.[ADDRESS_907352] safety, and in order to fulfill regulatory requirements , all SAEs 
(regardless of their relationship to Study Drug ) should be reported to the Sponsor  or designee 
within 24 hours of the Study Center’s first knowledge of the  event. The collection of SAEs will 
ISIS [ADDRESS_907353]’s  
follow-up period. An  Initial Serious Adverse Event Form should be completed and a copy should 
be faxed to the Sponsor  or designee.   
The contact [CONTACT_368140]:  
Attention:    
Ema
il:    
Fax:    
D
et
ailed information should be actively sought and included on Follow-Up Serious Adverse 
Event Forms as soon as additional information becomes available. All SAEs will be followed 
until resolutio n. SAEs that remain ongoing past the subject’s last protocol-specified follow-up 
visit will be evaluated by [CONTACT_37864]. If the Investigator and Sponsor agree the 
subject’s condition is unlikely to resolve, the Investigator and Sponsor wil l deter mine the 
follow-up requirement. 
9.4.[ADDRESS_907354]’s follow- up period. The Investigator will monitor each  
subject closely and record all observed or volunteered AEs on the Adverse Event Case Report 
Form.  
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opi[INVESTIGATOR_10463]. [IP_ADDRESS] Relationship to the Study Drug  
The event’s relationship to the Study Drug ( ISIS 703802 or placebo) is characterized by [CONTACT_144393]: 
• Related:   There is clear evidence that the event is related to the use of Study Drug , e.g., 
confirmation by [CONTACT_38000]- challenge test  
• Possible:   The event cannot be explained by [CONTACT_423]’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and Study Drug ( ISIS 703802 or placebo) administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions) or the temporal relationship to Study Drug ( ISIS 703802 or placebo) administration and/or exposure suggests that a 
causal relationship  is unlikely (For reporting purposes, Unlikely/Remote will be grouped 
together with Not Related)  

ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
63 • Not Related:   The event can be readily explained by [CONTACT_423]’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes 
no relationship exists between the event and Study Drug  
[IP_ADDRESS] Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ). Any AE 
not listed in  Appendix D  will be graded as follows: 
• Mild:  The event is easily tolerated by [CONTACT_368101]’s usual 
daily activities  
• Moderate:  The event causes the subject more discomfort and interrupts the subject’s 
usual daily activities  
• Severe: The event is incapacitating and causes considerable interference with the 
subject’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3).  
[IP_ADDRESS] Action Taken with Study Drug  
Action taken with Study Drug ( ISIS 703802 or placebo) due to the event is characterized by [CONTACT_144394]. 
• None: No changes were made to Study Drug ( ISIS 703802 or placebo) administration 
and dose 
• Permanently Discontinued:  Study drug was discontinued and not restarted 
• Temporarily Interrupted, Restarted – Same Dose : Dosing was temporarily interrupted  
or delayed due to the AE and restarted at the same dose 
• Temporarily Interrupted, Restarted − Reduced Dose:  Dosing was temporarily 
interrupted or delayed due to the AE and restarted at the next lower dose 
[IP_ADDRESS] Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for the AE  should be recorded on the 
Adverse Event Case Report Form . Treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  eCRF , as appropriate. 
[IP_ADDRESS] Outcome of the Adverse Event  
If the e vent is a non- serious AE , then t he event’s outcome is characterized by [CONTACT_38012]: 
• AE Persists:  Subject terminates from the trial and the AE continues 
• Recovered:  Subject recovered completely from the AE  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
64 • Became Serious:  The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity (if applicable):  AE severity changed  
If the event is an SAE , then the event’s outcome is characterized by [CONTACT_080]: 
• Ongoing:  SAE continuing 
• Persists (as non -serious AE):  Subject has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non-serious AE eCRF  (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:  Subject recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:  Subject died (the date of death should be ente red as the SAE resolution date) 
9.[ADDRESS_907355] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE . Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia. Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs. 
Clinically significant abnormalities will be monitored by [CONTACT_671602]. Laboratory abnormalities deemed not clinically significant (NCS) by [CONTACT_10555]. Similarly, laboratory abnormalities reported as AEs by [CONTACT_37724]. 
The Investigator is responsible for reviewing and signing all laboratory reports. The signed 
clinical laboratory reports will serve as source documents and should include the Investigator’s assessment of clinical significance of out of range/abnormal laboratory values . 
9.5.[ADDRESS_907356] is hospi[INVESTIGATOR_057]; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled (or was on a waiting list to be scheduled) prior to obtaining the subject’s  consent to 
participate in the study 
• The condition that required the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_204884]’s  consent to participate in the study and the timin g of the 
procedure or treatment  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
65 • The prescheduled or electi ve procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospi[INVESTIGATOR_063] 
9.5.3 Dosing Errors  
Study Drug ( ISIS 703802 or placebo) errors should be documented as Protocol Deviations. A 
brief description should be provided in the deviation, including whether the subject  was 
symptomatic (list symptoms) or asymptomatic, and the event accidental or intentional.  
Dosing details should be captured on the Dosing eCRF .  If the subject  takes a dose of Study 
Drug ( ISIS 703802 or placebo) that exceeds protocol specifications and the subject  is 
symptomatic, then the symptom(s) should be documented as an AE  and be reported per 
Section  9.4. 
Should an overdose occur , the Investigator or designee should refer to the Guidance to 
Investigators section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_907357] learning of the occurrence of pregnancy. Follow-up 
information including delivery or termination is reported by [CONTACT_10558]  ‘Follow-up’ on the 
Pregnancy Forms and reported within [ADDRESS_907358]’s 
responsibility.   
Female subject s: If a suspected pregnancy occurs while on the study (including follow-up), a 
pregnancy test will be performed.  The subject with a confirmed pregnancy will be imm ediately 
withdrawn from t reatment with Study Drug . However, the subject will be encouraged to 
complete the post- treatment follow -up portion of the study to the extent that study procedures do 
not interfere with the pregnancy. Regardless of continued study participation, the study physician 
will assist the subject  in getting obstetrical care and the progress of the pregnancy will be 
followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion). If the pregnancy results in the birth of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth.  Follow-up will be performed to the extent permitted by [CONTACT_368146]. 
Male subjects : The progress of the pregnancy of a male subject’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion). If the pregnancy results in the birth of a child, the Study Center and Sponsor may request access to the mother and infant’s medical records for an additional 8 weeks after 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
66 birth.  Follow- up will be performed to the extent permitted by [CONTACT_368146]. 
10. STATISTICAL CONSIDERATIONS   
10.1 Study Endpoints, Subsets, and Covariates 
10.1.1 Primary Endpoint 
Percent change in fasting TG level from Baseline at the primary analysis time point.  
10.1.2 Secondary Endpoints 
• Absolute and percentage change in ANGPTL3 protein, TC, LDL- C, HDL -C, VLDL -C, 
Non-HDL -C, ApoB (ApoB-48, ApoB-100), ApoCIII, ApoAI, FFA, Lp(a) 
• Absolute change in fasting plasma glucose, HbA1c, fasting insulin HOMA- IR, 
fructosamine and glycated albumin 
• Absolute and percent change in weight, SBP and DBP 
• Absolute and percent change in h epatic fat fraction (HFF) by [CONTACT_9268] -PDFF  
• Proportion of subjects  reaching hepatic fat fraction (HFF) ≤ 8% by [CONTACT_9268] -PDFF  
• Absolute change in Fatty Liver Index (FLI) 
• Absolute change in ALT and AST 
Evaluate the beneficial effect of ISIS 703802 on changes from Baseli ne at the primary analysis 
time point on: 
• Adipokines and related metabolic markers such as leptin, adiponectin, phospholipi[INVESTIGATOR_805] (e.g. 
ceramides, sphingolipi[INVESTIGATOR_805], diacylglycerol) 
• Body composition as measured by [CONTACT_671603] (S AT) 
and visceral adipose tissue (VAT), waist circumference, WHR (waist -to-hip ratio), and 
BMI  
   
 
 
  
 
 
 
 

ISIS [ADDRESS_907359] 24 patients. Considering 10% 
dropouts, [ADDRESS_907360]:  
• A treatment difference in mean triglycerides of 50% based on a between -patient standard 
deviation of 46% ( Jani et al. 2014)  and a two -sample t -test with an unadjusted alpha 
level of 0.05 with 93% power. 
• A treatment difference i n mean liver fat of 4.75% based on a between-patient standard 
deviation of 3.96% ( Tiikkainen et al. 2004)  and a two -sample t -test with an unadjusted 
alpha level of 0.05 with 96% power. 
A total of approximately 96 subjects  (32 subjects  per cohort, including 24 subjects  per cohort 
treated with ISIS 703802) will be randomized to ensure that the efficacy of ISIS 703802 will be 
adequately characterized in the study.  
10.3 Populations 
Full Analysis Set (FAS) : All subjects  who are randomized, received at least 1 dose of Study 
Drug (ISIS 703802 or placebo), and have a Baseline TG  assessment. The FAS represents the 
practically -feasible intent -to-treat (ITT) population as delineated in ICH Guideline E9. This 
population will be used for the prima ry analysis of efficacy.  
Per Protocol Set (PPS) : Subset of the FAS who received within [ADDRESS_907361] no major protocol violations 
that could compromise the interpretation of efficacy. Major violations will be determined prior to 
unblinding for statistical a nalysis. This population will be used for supportive inferences 
concerning efficacy.  
Safety Set:  All subjects  who are randomized and receive at least 1 dose of Study Drug. This 
population will be used for all safety analyses.  
PK Population:  All subjects  who are randomized and received at least [ADDRESS_907362] dose. This population will be used for 
analysis of PK data.  
10.4 Definition of Baseline  
Baseline for TG, ANGPTL3, TC, LDL -C, HDL -C, VLDL -C, Non- HDL -C, ApoB (ApoB-48, 
ApoB-100), ApoCIII, ApoAI, FFA, Lp(a), and other lipid measurements will be defined as the 
average of Day [ADDRESS_907363] 
error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for 
continuous variables, and counts and percentages for categorical variables will be used to summarize most data. Where appropriate, p -values will be reported. All statistical tests will be 
conducted using 2- sided tests with 5% Type I error rate unless otherwise stated.   
10.6.[ADDRESS_907364]  disposition.  
10.6.2 Safety Analysis  
[IP_ADDRESS] Adverse Events  
Treatment duration and amount of Study Drug (ISIS 703802 or placebo) received will be 
summarized by [CONTACT_1570]. Subject incidence rates of all AEs will be tabulated by [CONTACT_11189], and by [CONTACT_6213]. Narratives of treatment -emergent 
deaths, serious and significant AEs, including early withdrawals due to AEs, will also be provided.  
All treatment- emergent AEs, all treatment- emergent AEs potentially related to Study Drug, all 
treatment -emergent serious AEs, and all treatment -emergent serious AEs potent ially related to 
Study Drug ( ISIS 703802
 or placebo) will be summarized.  
[IP_ADDRESS] Clinical Laboratory Data  
Laboratory tests to ensure subject  safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, complement, e tc., will be summarized by [CONTACT_368147]. These safety variables will also be presented as change and percent change 
from Baseline over time after Study Drug ( ISIS 703802 or placebo) administration, as 
appropriate. In addition, the number of subjects who experience abnormalities in clinical laboratory evaluations will be summarized by [CONTACT_1570].  
[IP_ADDRESS] Vital Signs and Examinations  
Vital sign and ECG measures will be tabulated by [CONTACT_1570].  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
69 10.6.3 Efficacy Analysis  
[IP_ADDRESS] Analysis of Primary Efficacy Endpoint  
The primary analysis of the primary endpoint will be the pairwise comparison of percent change 
from Baseline to primary analysis time point in TG between ISIS 703802 treatment groups and 
pooled placebo group in the FAS. The data will be analyzed using an analysis of covariance (ANCOVA) model with the Baseline TG  as a covariate. Missing data may be handled by [CONTACT_671604] (Schafer 1997; Shaffer 1999).  
The primary efficacy analysis will take place after the last subject  has completed the primary 
analysis time point, and the database has been locked.  
The following sensitivity analyses will be conducted:  
• The primary analysis will be repeated in the PPS  
• The primary efficacy endpoint will be analyzed using a Wilcoxon Rank Sum test on both 
FAS and PPS, and the treatment effect will be estimated using Hodges -Lehmann 
estimator  
Additional sensitivity analyses may be conducted as appropriate; the details of these analyses 
will be outlined in the SAP.  
[IP_ADDRESS] Analysis of Secondary Efficacy Endpoints  
• Absolute and percentage change at the primary analysis time point in ANGPTL3 protein, 
TC, LDL -C, HDL -C, VLDL -C, Non- HDL -C, ApoB (ApoB-48, ApoB-100), ApoCIII, 
ApoAI, FFA, Lp(a) will be compared between each AKCEA- ANGPTL3 -L
R treatment 
group and pooled placebo group using an ANCOVA model with Baseline as covariate  
• Absolute change in fasting plasma glucose, HbA1c, fasting insulin HOMA- IR, 
fructosamine and glycated albumin will be compared between each ISIS 703802  
treatment group and pooled placebo group using an ANCOVA model with Baseline as 
covariate  
• Absolute and percent change in weight, SBP and DBP will be compared between each ISIS 703802
 treatment group and pooled placebo group using an ANCOVA model with 
Baseline as covariate  
• Absolute and percent change in hepatic fat fraction (HFF) by [CONTACT_9268] -PDFF will be 
compared between each ISIS 703802  treatment group and pooled placebo group using an 
ANCOVA model with Baseline as covariate  
• Proportion of subjects  reaching hepatic fat fraction (HFF) ≤ 8% by [CONTACT_9268] -PDFF at the 
primary analysis time point will be compared between each ISIS 703802  treatment group 
and pooled placebo group using a logistic regression model with Baseline HFF as a 
covariate.  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
70 • Absolute change in Fatty Liver Index (FLI) will be compared between each ISIS 703802  
treatment group and pooled placebo group using an ANCOVA model with Baseline as 
covariate  
• Absolute change in ALT and AST will be compared between each ISIS 703802  treatment 
group and pooled placebo group using an ANCOVA model with Baseline as covariate  
• Absolute change in Adipokines and related metabolic markers such as leptin, 
adiponectin, phospholipi[INVESTIGATOR_805] (e.g. ceramides, sphingolipi[INVESTIGATOR_805], diacylglycerol) will be 
compared between each ISIS 703802  treatment group and pooled placebo group using an 
ANCOVA model with Baseline as covariate  
• Absolute change in Body composition as measured by [CONTACT_671605] (SAT) and visceral adipose tissue (VAT), waist circumference, WHR (waist -to-hip ratio), and BM will be compared between each ISIS 703802
 treatment group 
and pooled placebo group using an ANCOVA model with Baseline as covariate  
 
• 
 
 
 
10.6.[ADDRESS_907365]- treatment concentrations of ISIS 703802 in plasma (as total 
full-length oligonucleotides, including fully conjugated, partially conjugated, and unconjugated 
ISIS 703802) will be determined and summarized by [CONTACT_474292] (IM) status using descriptive statistics.  
In addition, plasma terminal elimination half -life of ISIS [ADDRESS_907366]-treatment follow -up data if data permits.   
Additionally, f or subjects in the PK subgroup only, PK parameters will be calculated using 
non-compartmental methods. The maximum plasma concentration (C max) and time to reach C max 
(Tmax) values  will be  obtained directly from the plasma concentration -time data. The area under 
the plasma concentration -time curve (AUC) values after the first dose and last dose will be 
calculated using the linear trapezoidal rule.  Other PK parameters may be calculated at th e 
discretion of the PK scientist. Plasma PK parameters will be summarized using descriptive statistics with and without stratification by [CONTACT_84308].   
Exposure-response relationships between selected PD [e.g., TG ] and PK measures ( e.g., plasma 
troug h concentrations) may be explored (including with and without stratification by [CONTACT_10638]) 
in this study, or in a separate population PK analysis combined with other clinical studies.  
The IM of ISIS 703802
 will be assessed before, during, and after treatm ent with Study Drug 
(ISIS 703802  or placebo). The IM incidence (number) and incidence rate (percent) will be 

ISIS [ADDRESS_907367]  level by [CONTACT_10566], as 
the total number of and percent of evaluated subjects with antibody negative, positive, and 
unknown status. Study subjects  with positive anti-ISIS 703802  antibody status may be further 
classified (when applicable) as being either ‘persistent’, ‘transient’, or not determinable. 
Potential relationships  of IM with selected efficacy, safety, and PK measures may be evaluated.  
Additional details regarding the PK and IM analysis will be described in the SAP.  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential subject  population, based on an English version provided by [CONTACT_16015]. 
Before a subject’s  participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the subject  or legally acceptable representative after adequate explanation 
of the aims, methods, anticipated benefits, and potential hazards of the study and before any 
protocol- specific screening procedures or any Study Drug ( ISIS 703802
 or placebo) are 
administered. The subject or legally acceptable representative must be given sufficient time to 
consider whether to participate in the study.   
The acquisition of informed consent and the  subject’s  agreement or refusal to notify his/her 
primary care physician  should be documented in the subject’s  medical records and the informed 
consent form should be signed and personally dated by [CONTACT_356967] a legally acceptable 
representative and by [CONTACT_28490] (not necessarily an Investigator). The original signed informed consent form should be retained in the Study 
Master File and in any other locations required by [CONTACT_671606], and a copy of the signed 
consent form should be provided to the subject  or legally acceptable representative. 
If a potential subject  is illiterate or visually impaired and does not have a legally acceptable 
representative, the Investigator must provide an impartial witness to read the informed consent form to the subject  and must allow for questions. Thereafter, both the subject  or legally 
acceptable representative and the witness must sign the informed consent form to attest that informed consent wa s freely given and understood. 
The sponsor shall maintain all records referred to in the applicable Regulations for a period of [ADDRESS_907368] of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated October 2002 the applicable regulations and guidelines of current Good Clinical Practice (GCP E6R2 ) as 
well as the demands of national drug and data protection laws and other applicable regulatory requirements will be strictly followed.  
11.3 Independent  Ethics Committee/Institutional Review Board  
A copy of the protocol, proposed informed consent form, other written subject  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval. A 
ISIS [ADDRESS_907369] be received b y the 
Sponsor or designee before recruitment of subjects  into the study and shipment of Study Drug .A 
copy of the written approval of any other items/materials that must be approved by [CONTACT_671607]/IRB must also be received b y the Sponsor or designee before recruitment of 
subjects  into the study and shipment of Study Drug .  The Investigator’s Brochure must be 
submitted to the IEC/IRB for acknowledgement.  
The Investigator must submit to and, where necessary, obtain approval from the  IEC/IRB  for all 
subsequent protocol amendments and changes to the informed consent document. The 
Investigator should notify the IEC/IRB  of deviations from the protocol in accordance with ICH  
GCP  Section  4.5.2. The Investigator should also notify the IEC/IRB  of SAEs  occurring at the 
Study Center  and other AE  reports received from the Sponsor or designee, in accordance with 
local procedures.  
The I nvestigator will be responsible for obta ining annual IEC/IRB  approval/renewal throughout 
the duration of the study. Copi[INVESTIGATOR_5699]’s reports , all IEC/IRB  submissions and the 
IEC/IRB  continuance of approval must be sent to the Sponsor or designee. 
11.[ADDRESS_907370]’s confidentiality is maintained. On the case report 
forms or other documents submitted to the Sponsor or designee, subjec ts should be identified by 
[CONTACT_10573] (if permitted by [CONTACT_1769]) and a subject  identification  number only. Documents that are 
not for submission to the Sponsor or designee (e.g., signed informed consent forms) should be 
kept in strict confidence by [CONTACT_737]. 
In compliance with Federal and local regulations/ICH GCP Guide lines , it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB direct access to review the subject’s  original medical records for 
verification of study- related procedures and data. Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study. The I nvestigator is obligate d to inform and obtain the consent of the subject  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the subject . 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.[ADDRESS_907371] be obtained for all protocol amendments and amendments 
to the informed consent document. The regulatory authority and IEC/IRB must be informed of 
all amendments and give approval for any amendments likely to affect the safety of the subjects 
or the conduct of the trial. The Investigator must send a copy of the approval letter from the IEC/IRB t o the Sponsor  or designee.  
12.[ADDRESS_907372]. The  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
73 Investigator/Sponsor or designee should notif y the IEC/IRB in writing of the trial’s completion 
or early termination and send a copy of the notification to the Sponsor or designee. 
12.3 Study Documentation and Storage  
An electronic case report form (eCRF) utilizing an Electronic Data Capture (EDC) ap plication 
will be used for this study. 
The Investigator should ensure that all  appropriately qualified persons to whom he/she has 
delegated trial duties  are recorded on a Sponsor-approved Delegation of Site Responsibilities 
Form . 
Source documents are original documents, data, and records from which the subject’s case report 
form data are obtained. These include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, laboratory and pharmacy records, diaries , imaging , and correspondence . Case report form 
entries may be considered source data if the case report form is the site of the original recording (i.e., there is no other written or electronic record of data).   
The Investigator and S tudy Center staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6R2 ), suitable for inspection at any time by [CONTACT_671608]/or applicable r egulatory authorities. Elements should include: 
• Subject files containing completed case report forms, informed consents, and supporting 
copi[INVESTIGATOR_10467] 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copi[INVESTIGATOR_37569] -study documentation and all correspondence to and from the IEC/IRB  and the 
Sponsor  or designee  
• If drug supplies are maintained at the Study Center, proof of receipt, Study Drug Product Accountability Record, Return of Study Drug Product for Destruction, final Study Drug  
product reconciliation, and all drug- related correspondence  
In addition, all original source documents supporting entries in the case report forms must be maintained and be readily available.  
No study document should be destroyed without prior written agreement between the Sponsor  or 
designee  and the Investigator.  Should the I nvestig ator wish to assign the study records to 
another party or move them to another location, he/she must notify the Sponsor or designee. 
12.[ADDRESS_907373], inspecting the various records of the trial (e.g., case report forms and other pertinent data) provided that subject  confidentiality is respected.  
The Sponsor monitor or designee is responsible for inspecting the case report forms at regular 
intervals throughout the study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research. 
ISIS [ADDRESS_907374]  medical records and other study- related records 
needed to verify the entries on the case report forms. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the 
course of these monitoring visits, including delays in completing case report forms, are resolved. 
In acco rdance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by [CONTACT_10576]’s Clinical Quality Assurance Department (or designees).  
Inspection of Study Center facilities (e.g., pharmacy, drug storage areas, laboratories) and review 
of study- related records will occur to evaluate the trial conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements. 
To ensure the quality of clinical data a clinical data management review will be p erformed on 
subject  data received by [CONTACT_16015]. During this review, subject data will be 
checked for consistency, omissions, and any apparent discrepancies. In addition, the data will be 
reviewed for adherence to the protocol and GCP. To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be 
sent to the Study Center  for completion and return to Sponsor or designee . 
The Principal Investigator [INVESTIGATOR_10469]. These signatures will indicate that the Principal Investigator [INVESTIGATOR_10470], the data queries, and the Study Center notifications, and agrees with the content. 
12.[ADDRESS_907375] use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws.  Subjects  will b e treated and/or compensated for any study -
related illness/injury in accordance with the information provided in the Compensation for Injury section of the Informed Consent document.  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
75 13. REFERENCES  
American Diabetes Association  (ADA) . Standards of Medical  Care in Diabetes. Diabetes Care 2008;  31(1): S12-
S54. 
Adiels M, Olofsson SO, Taskinen MR,  et al. Overproduction of very low -density lipoproteins is the hallmark of the 
dyslipi[INVESTIGATOR_671570].  Arterioscler Thromb Vasc Biol . 2008 Jul;  28(7):1225- 36. 
Altmann KH, Dean NM, Fabbro D, et al.  Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals. Chimia 1996; 50: 168 -176. 
Assy N et al . Fatty infiltration of liver in hyperlipi[INVESTIGATOR_671571]. Dis. Sci 2000 .  
Brandt TA, Lee RG, Digenio A, et al. ISIS -ANGPTL3RX, an antisense inhibitor to angiopoietin -like 3, reduces 
plasma lipid levels in mouse models and in healthy human volunteers. At herosclerosis 2015; 241: e30- e31. 
Büller HR, Cohen AT, Davidson B, et al.  Idraparinux versus standard therapy for venous thromboembolic disease. 
New England Journal of Medicine 2007; 357: 1094- 1104.  
Crooke ST and Bennett CF. Progress in antisense ol igonucl eotide  therapeutics. Annual Review of Pharmacology 
and Toxicology 1996; 36: 107 -129. 
Dake AW  and Sora ND .  Diabetic Dyslipi[INVESTIGATOR_671572]: An Update on Current Concepts and Management 
Guidelines of Diabetic Dyslipi[INVESTIGATOR_035] . Am J Med Sci. 2016 Apr;351(4):361- 5. 
Dorato MA and Engelhardt JA. The no -observed -adverse -effect -level in drug safety evaluations: use, issues, and 
definit ion(s). Regul Toxicol Pharmacol.  2005; 42(3): 265- 74. 
Everds N, Li N, Bailey K, et al. Unexpected thrombocytopenia and anemia in cynomolgu s monkeys induced by a 
therapeutic human monoclonal antibody. Toxicol Pathol. 2013; 41(7):951- 69 
FDA guidance for industry, “Drug- Induced Liver Injury: Premarketing Clinical Evaluation,” issued by [CONTACT_941] U.S. 
Department of Health and Human Services, Food and Drug Administration, July 2009  
https://www.fda.gov/downloads/Guidances/UCM174090.pdf  
Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor -α phosphorothioate 2ʹ-O- (2-
methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003; 31: 1419–
1428.  
Graham MJ , Lee RG , Brandt TA , et al. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense 
Oligonucleotides . N Engl J Med 2017; 377:222- 232. 
Henry SP, Kim TW, Kramer -Stickland K, et al. Toxicologic properties of 2ʹ -O-methoxyethyl chimeric antisense 
inhibitors in animals and man. In: Crooke S, editor, Antisense Drug Technology, 2nd ed. CRC Press, B oca Raton, 
FL 2008; 10: 327- 364. 
Huszar D, Varban ML, Rinninger F, et al. Increased LDL cholesterol and atherosclerosis in LDL receptor -deficient 
mice with attenuated expression of scavenger receptor B1. Artherioscler Thromb Vasc Biol 2000; 20(4): 1068- 1073.  
Inukai K,  Nakashima Y,  Watanabe M, et al . ANGPTL3 is increased in both in sulin -deficient and -resistant diabetic 
states . Biochem. Biophys. Res. Commun.  2004;  317(4):1075 –1079. 
Inoue H, Hayase Y, Iwai S, et al. Sequence -dependent hydrolysis of RNA using modified oligonucleotide splints 
and RNase H. FEBS Letters 1987; 215:  327-330. 
Jani R, Pai V, Jha P, Jariwala  G, Mukhopadhyay  S, Bhansali  A, Joshi  S. A Multicenter, Prospective, Randomized, 
Double -Blind  Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4mg Compared with Placebo in Type 
2 Diabetes  Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI) . 
DIABETES TECHNOLOGY & THERAPEUTICS Volume 16, Number 2, 2014  
Leite NC ,  Salles GF, Araujo AL , et al. Prevalence and associated  factors  of non-alcoholic fatty liver 
disease  in patients  with type -2 diabetes mellitus.  Liver  Int. 2009; 29(1):113- 9.  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
76 Martin -Campos JM, Roig R, Mayoral C, et al. Identification of a novel mutation in the ANGPTL3 gene in two 
families diagnosed of familial hypobetalipoproteinemia without APOB mutation. Clin Chim Acta 2012; 413: 552 -
555. 
McKay RA, Miraglia LJ, Cummins LL, et al . Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression.  J Biol Chem 1999; 274:1715- 1722.  
Minicocci  I, Montali A, Robciuc MR, et al. Mutations in the ANGPTL3 gene and familial combined hypolipi[INVESTIGATOR_035]: 
a clinical and biochemical characterization .  J Clin Endocrinol Metab.  2012 Jul; 97(7):E1266- 75. 
Monia  BP, Lesnik EA, Gonzalez C, et al . Evaluation of 2 ′-modified oligonucleotides con taining 2 ′-deoxy gaps as 
antisense inhibitors of gene exp ression. J Biol Chem 1993; 268: [ZIP_CODE]- [ZIP_CODE]. 
Musunuru K, Pi[INVESTIGATOR_19961], Do R, et al. Exome sequencing, ANGPTL3 mutati ons, and familial combined 
hypolipi[INVESTIGATOR_035]. N Engl J Med 2010; 363: 2220- 2227.  
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III) . Third Report of  the National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;  106(25):3143- 421. 
Noto D, Cefalu A B, Valenti V, et al. Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined 
hypolipi[INVESTIGATOR_035]. Arterioscler Thromb Vasc Biol 2012; 32: 805- 809. 
Pi[INVESTIGATOR_20664] L, Favari E, Magnolo L, et al. Characterization of three kindreds with familial combined hypolipi[INVESTIGATOR_671573] -of-function mutations of ANGPTL3. Circ Cardiovasc Genet 2012; 5: 42- 50. 
Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2): 168 -86. 
Prakash TP, Graham MJ, Yu J, et al . Targeted delivery of antisense oligonucleotides to hepatocytes using 
triantennary N -acetyl galactosamine improves potency 10 -fold in mice. Nucleic Acids Res 2014; 42: 8796- 8807.  
Robciuc  MR,  Maranghi M, Lahikainen A,  et al.  ANGPTL3 deficiency is associated with increased insulin 
sensitivity, lipoprotein lipase activity, and d ecreased serum free fatty acids.  Arterioscler Thromb Vasc Biol . 2013 
Jul; 33(7):1706- 13.  
Romeo  S, Yin W, Kozlitina J, et al. Rare loss -of-function mutations in ANGPTL family members contribute to 
plasma triglyceride levels in humans. J Clin Inv 2009; 119(1): 70- 79. 
Schafer JL. Analysis of Imcomplete Multivariate Data. Chapman and Hall, A CRC Press Company,  US 1997.  
Shaffer HJ, Hall MN, Vander Bilt J. Estimating the Prevalance of Disordered Gambling Behavior in the [LOCATION_002] and Canada: A Research Synthesis. Am J Public Health.  1999 Sep;  89(9):1369- 76. 
Schreyer SA, Vick C, Lystig TC, et al. LDL receptor but not apolipoprotein E deficiency increase diet -induced 
obesity and diabetes in mice. Am J Physiol Endocrinol Metab 2002; 282: E207- E214.  
Shulman, GI.  Ectopic Fat in Insulin Resistance, Dyslipi[INVESTIGATOR_035], and Cardiometabolic Disease N  Engl J Med 2014; 
371:1131- 1141.  
Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev 1995; 75: 591- 609. 
Targher G , Day CP, Bonora E. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease . N 
Engl J Med 2010; 363:1341- 1350.  
Tiikkainen M, Hakkinen A, Korsheninnikova E, Tuulikki N, Ma¨kimattila S, Yki -Ja¨rvinen H. Effects of 
Rosiglitazone and Metformin on Liver Fat  Content, Hepatic Insulin Resistance, Insulin Clearance,  and Gene 
Expre ssion in Adipose Tissue in Patients With  Type 2 Diabetes . Diabetes 53:2169 –2176, 2004. 
Tsuchiya H, Ikeda Y, Ebata Y, et al. Retinoids ameliorate insulin resistance in a leptin -dependent manner in mice. 
Hepatology 2012: 56(4): 1319 -1330.  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
77 Vernon G , Baranova A, Younossi ZM. Systematic review: The epi[INVESTIGATOR_671574] . Aliment Pharmacol Ther. 2011; 34(3):274- 85. 
Wang Y , McNutt MC , Banfi S , et al. Hepatic ANGPTL3 regulates adipose tissue energy homeostasis.  Proc Natl 
Acad Sci US A 2015;  112:[ZIP_CODE]- [ZIP_CODE]. 
Zhang H, Löwenberg EC, Crosby [CONTACT_37738], et al. Inhibition of the intrinsic coagulation pathway Factor XI by [CONTACT_37739]: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010;  116: 4684- 4692.   
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 3 
Protocol   21 March  2019 
 
78 14. APPENDICES  
 
 
 
  
 
  
 
 
Appendix A  Schedule of Procedures 
 
Schedule of Procedures – Weekly Dosing  
Schedule of Procedures – Every 4 -Week Dosing 
 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
79 Appendix A  Schedule of Procedures – Weekly Dosing 
 Screen ingr 
Treatment Period  Follow -up 
Period  Run-in# Qual† 
Study Week  -5 to -1 -1 to 0  1 1 5 9 13 17 21 25 26 27/ET  4* 8* 13* 
Study Day  -35 to -8 -7 to -1 1 2a 29 57 85 113 141 169 176 177a 178a 183 *Weeks from 
the end of 
treatment 
periodq 
Visit and Testing Window +/ - Days  0 0 0 0 2 2 2 3 3 3 3 0 0 3 3 3 3 
Informed Consent  X                 
Outpatient Visit  X X X X X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria  X X X               
Medical History  X                 
Vital Signs  X  X  X X X X X X X    X X X X 
Physical Examination b X  X  X  X       X X X  X 
Waist circumference/ WHR    X    X       X    
 Body Weight and Height  c X X X  X X X X X X X    X X X X 
12- lead ECG (triplicate)  X  X  X  X  X     X X X X 
Ultrasoundp  X                 
MRI  Xd, s     X       X    
24-Hour Urine for Creatinine 
Clearance and Protein   X                
Extended Urinalysis e X  EVERY 14 DAYS (+/- 2 days) e, f X X X    X X X X 
Renal Biomarkers g X  EVERY 14 DAYS (+/- 2 days) f, g X X X    X Xh Xh Xh 
Serum Creatinine and Cys -C i, j, k X  EVERY 14 DAYS (+/- 2 days) f, i X X X    X X X X 
Chemistry Panel j , k X  EVERY 14 DAYS (+/- 2 days) f X X X    X X X X 
Hematology  j, k X  X HEMATOLOGY PERFORMED EVERY 14 DAYS (+/- 2 days) f, k   Xh Xh Xh 
Coagulation  X  X    X       X   X 
Hepatitis B, C, HIV  X                 
Thyroid Panel  X                 
 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
80 Appendix A  Schedule of Procedures – Weekly Dosing Continued  
 Screen ingr 
Treatment Period  Follow -up 
Period  Run-in# Qual*  
Study Week  -5 to -1 -1 to 0 1 1 5 9 13 17 21 25 26 27/ET  4* 8* 13* 
Study Day  -35 to -8 -7 to -1 1 2a 29 57 85 113 141 169 176 177a 178a 183 * Weeks from 
the end of 
treatment 
periodq 
Visit and Testing Window +/ - Days  0 0 0 0 2 2 2 3 3 3 3 0 0 3 3 3 3 
Liver Biomarkers    X    X  X      X   X 
Plasma PK - ISIS 703802 l   X3 X1 X X X X X  X3 X1 X2 X X X X 
Anti-ISIS 703802 Antibodies    X  X X X  X     X X   X 
FSH (women only, if applicable)  j, 
m X                 
Serum Pregnancy Test  m X  X  X X X X X X    X X X X  
Archived Serum & Plasma 
Samples  j, n   X   X  X X      X X X X  
PD Panel  and phospholipi[INVESTIGATOR_805] j X X X  X X X X X  X   X X X X 
Extended Lipid Panel  j X X X  X X X X X  X   X X X X 
HbA1C j X  X    X       X   X 
FPG, and delipi[INVESTIGATOR_37489], insulin  
j X  X  X X X X X  X   X X X X 
Biomarkers of Inflammation    X    X       X   X 
Study Drug:  SC Injection    EVERY WEEK SUBCUTANEOUS ADMINISTRATION OF STUDY DRUG  
(Week 1 through Week 26/Day 176) o     
Adverse Events  X  X X X X X X X X X X X X X X X 
Concomitant Medication  X  X X X X X X X X X X X X X X X 
† Qual  =Qualification  
# Subjects on stable diet known to the investigator and followed at  the site may go from Screening to qualification without the diet run-in period.   
 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
81 Appendix A  Schedule of Procedures – Weekly Dosing Continued  
All procedures and study samples are to be done pre-dose at respective visits, unless specified  
a Visit only required for subjects  in PK subgroup.  
b Full physical exam will be performed at the Screening visit and an abbreviated physical exam will be performed during treatment and follow -up periods.  
c     Height only required at Screening.  
d     MRI will only be performed during Screening after all other eligibility criteria are met .  MRI should be performed 10 days (+/ - 2 days)  prior to anticipated Day [ADDRESS_907376] be no more than 
4 weeks apart during the treatment period  
g Urine samples for renal biomarkers will be collected.  Sample analysis will be conducted in accordance with Safety Monitoring for Renal Function 
(Section 8.5.2). 
h During follow -up period, hematology sampling for platelet values are taken every 14 days (+/ - 2 days)  for [ADDRESS_907377] 10 hours and preferably not more than 12 hours, unless tests are repeated for safety reasons.  
k If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to clumpi[INVESTIGATOR_007], hemolysis or quantity not sufficient) a repeat blood 
specimen should be re- drawn as soon as possible (ideally within 7 days).  All platelet count results will be reviewed promptly (within 48 hours of receipt) by [CONTACT_671609] 6.2.1 .  Any case of a platelet count ≤ 50,000/mm3 should be reported in an expedited fashion to the Sponsor.  
l      Refer to Appendix C  for PK Sampling schedule.  
m Women who are not surgically sterile or post -menopausal.  
n Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or AEs (e.g., measurement of cytokine and/or 
chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) and will be retained until completion of the final 
study report. 
o Last dose of Study Drug will be administered at Week 26/Day 176 +/ - [ADDRESS_907378] documented history of hepatic steatosis as 
determined . by [CONTACT_92156] (CT scan, MRI or US) . Ultrasound may be repeated at the discretion of the PI. Results of Ultrasound must be available and confirm 
eligibility prior to MRI being performed.  
q Treatment period is defined as the time from the first dose through one dosing interval post last dose.  
r If a subject was screened and failed to meet eligibility under a previous protocol , the subject may be screened under the current protocol . 
s If a subject was screened and had an MRI, but failed to meet eligibility under a  previous protocol, the MRI during rescreening may not need to be repeated. 
The need to repeat an MRI for such subjects should be discussed with the Medical Monitor.  
 
Time (time is in reference to Study Drug administration):   
[ADDRESS_907379] SC injection for subjects on PK subgroup.  
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
82  
Appendix A  Schedule of Procedures – Every 4 -Week Dosing 
 Screen ingr 
Treatment  Period  Follow -up Period  
Run-in# Qual† 
Study Week  -5 to -1 -1 to 0 1 1 5 9 13 17 21 22 23 25/ET  4* 8* 13* 
Study Day  -35 to -8  -7 to -1 1 2a 29 57 85 113 141 142a 143a 148a 155a 169 * Weeks from the 
end of treatment 
periodq 
Visit and Testing Window +/ - Days  0 0 0 0 2 2 2 3 3 0 0 0  0  3 3 3 3 
Informed Consent  X                 
Outpatient Visit  X X X X X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria  X X X               
Medical History  X                 
Vital Signs  X  X  X X X X X   X  X X X X 
Physical Examination b X  X  X  X       X X X X 
Waist circumference/ WHR    X    X       X    
Body Weight and Height c X X X  X X X X X     X X X X 
12- lead ECG (triplicate)  X  X  X  X  X     X X X X 
Ultrasoundp  X                 
MRI  Xd, s     X       X    
24-Hour Urine for Creatinine Clearance 
and Protein   X                
Extended Urinalysis e X  EVERY 14 DAYS (+/- 2 days) e, f X X     X X X X 
Renal Biomarkers g X  EVERY 14 DAYS (+/ - 2 days) f, g X X     X Xh Xh  Xh  
Serum Creatinine and Cys -C i, j, k X  EVERY 14 DAYS (+/ - 2 days) f, i X X     X X X X 
Chemistry Panel j  , k X  EVERY 14 DAYS f X X     X X X X 
Hematology  j, k X  X  HEMATOLOGY PERFORMED EVERY 14 DAYS (+/- 2 days)  f, k  Xh Xh Xh 
Coagulation  X  X    X       X   X 
Hepatitis B, C, HIV  X                 
Thyroid Panel  X                 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
83  
Appendix A  Schedule of Procedures – Every 4 -Week Dosing Continued  
 Screen ingr 
Treatment  Period  Follow -up Period  
Run-in# Qual*  
Study Week  -5 to -1 -1 to 0  1 1 5 9 13 17 21 22 23 25/ET  4* 8* 13* 
Study Day  -35 to -8 -7 to -1 1 2a 29 57 85 113 141 142a 143a 148a 155a 169 * Weeks from the 
end of treatment 
periodq 
Visit and Testing Window +/ - Days  0 0  0 0 2 2 2 3 3 0 0 0  0  3 3 3 3 
Liver Biomarkers    X    X  X     X   X 
Plasma PK - ISIS 703802   l   X3 X1 X X X X X3 X1 X2 X X X X X X 
Anti-ISIS 703802 Antibodies    X  X X X  X     X X  X 
FSH (women only, if applicable)  j, m X                 
Serum Pregnancy Test  m X  X  X X X X X     X X X X 
Archived Serum & Plasma Samples  j, n   X   X  X X     X X X X 
PD Pane l and phospholipi[INVESTIGATOR_805]  j X X X  X X X X X     X X X X 
Extended Lipid Panel  j X X X  X X X X X     X X X X 
HbA1C j X  X    X       X   X 
FPG, and delipi[INVESTIGATOR_37489], 
insulin j X  X  X X X X X     X X X X 
Biomarkers of Inflammation     X    X       X   X 
Study Drug:  SC Injection    EVERY 4 -WEEK SUBCUTANEOUS ADMINISTRATION OF STUDY DRUG  
(Week 1 through Week 21/Day 141) o    
Adverse Events  X  X X X X X X X X X X X X X X X 
Concomitant Medication  X  X X X X X X X X X X X X X X X 
†Qual  =Qualification  
# Subjects on stable diet known to the investigator and followed at the site may go from Screening to qualification without the diet run-in period.   
 
 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
84 Appendix A  Schedule of Procedures – Every 4 -Week Dosing Continued  
All procedures and study samples are to be done pre-dose at respective visits, unless specified  
a Visit only required for subjects  in PK subgroup.  
b Full physical exam will be performed at the Screening visit and an abbreviated physical exam will be performed during treatment and follow -up periods.  
c     Height only required at Screening.  
d     MRI will only be performed during Screening after all other eligibility criteria are met .  MRI should be performed 10 days (+/ - 2 days)  prior to anticipated Day [ADDRESS_907380] be no more than 
4 weeks apart during the treatment period  
g Urine samples for renal biomarkers will be collected.  Sample analysis will be conducted in accordance with Safety Monitoring for Renal Function 
(Section 8.5.2). 
h During the follow -up period, hematology sampling for platelet values should continue to be taken every 14 days (+/- 2 days)  for 6 weeks after Week 27/EOT , 
then at Week 4, Week 8, and Week [ADDRESS_907381] 10 hours and preferably not more than 12 hours, unless tests are repeated for safety reasons.  
k If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to clumpi[INVESTIGATOR_007], hemolysis or quantity not sufficient) a repeat blood 
specimen should be re- drawn as soon as possible (ideally within 7 days).  All platelet count results will be reviewed promptly (within 48 hours of receipt) by [CONTACT_671609] 6.2.1 .  Any case of a platelet count ≤ 50,000/mm3 should be reported in an expedited fashion to the Sponsor . 
l      Refe r to Appendix C  for PK Sampling schedule.  
m Women who are not surgically sterile or post -menopausal.  
n Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or AEs (e.g., measurem ent of cytokine and/or 
chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) and will be retained until completion of the final 
study report.  
o Last dose of Study Drug will be administered at Week 21/Day 1 41 +/ - [ADDRESS_907382] a documented history of hepatic steatosis as 
determined.by [CONTACT_9661] (CT scan, MRI or US) . Ultrasound may be repeated at the discretion of the PI. Results of Ultrasound must be available and confirm 
eligibility prior to MRI being performed.  
q Treatment period is defined as the time from the first dose through one dosing interval post last dose.  
r If a subject was screened and failed  to meet eligibility under a previous protocol , the subject may be screened under the current protocol.  
s If a subject was screened and had an MRI, but failed to meet eligibility under a previous protocol, the MRI during rescreening may not need to be repeated. 
The need to repeat an MRI for such subjects should be discussed with the Medical Monitor.  
 
Time (time is in reference to Study Drug administration):  
[ADDRESS_907383] of Laboratory Analytes 
Clinical Chemistry Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Cholesterol  
• Uric Acid  
• Total bilirubin 
• Direct (conjugated) bilirubin  
• Indirect (unconjugated) bilirubin  
• ALT  
• AST  
• Alkaline phosphatase  
• Creatinine kinase 
• GGT  
• Cys-C 
 
PD Panel  
• ANGPTL3  
• Insulin  
• Proinsulin  
• C-peptide  
• Fructosamine  
• Glycated albumin  
• Delipi[INVESTIGATOR_671575]  
• Fasting Plasma Glucose  
 Screening Tests  
• Hepatitis B surface 
antigen  
• Hepatitis C antibody  
• HIV antibody  
• FSH (women only)  
• Serum βhCG  
• TSH  
• Free T4  
• Free T3  
 
Coagulation  
• aPTT (sec)  
• PT (sec)  
• INR 
 
Extended Lipid Panel  
• Total Cholesterol 
(TC)  
• LDL cholesterol 
(LDL -C) 
• HDL cholesterol (HDL -C) 
• Non-HDL cholesterol 
(non-HDL -C) 
• Triglycerides (TG)  
• VLDL  cholesterol 
(VLDL -C) 
• Lp(a)  
• FFA 
• ApoB -48 
• ApoB -100 
• ApoB  
• ApoCIII 
• Apo A-1 Hematology 
• Red blood cells  
• Hemoglobin 
• Hematocrit  
• MCV, MCH, MCHC  
• Platelets  
• White blood cells  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1 
• ISIS 703802  levels in 
plasma  
 
Immunogenicity  
• Anti-ISIS 703802  
antibodies  
 
Liver Biomarkers (a poptosis 
and fibrosis ) 
• CK18  
• PI[INVESTIGATOR_671576]  
• hs-CRP  
• IL-6 
• IFN gamma  
• TNF alpha  
• Leptin  
• Adiponectin  Extended Urinalysis  
• Routine Urinalysis  
- Color  
- Appearance  
- Specific gravity  
- pH 
- Protein  
- Red Blood  Cells  
- Glucose  
- Ketones  
- Bilirubin  
- Urobilinogen  
- Leukocyte esterase  
- Nitrate  
• Microscopic examination  
• P/C Ratio (UPCR)  
• A/C Ratio (UACR)  
 
Renal Urine Biomarkers2 
• NGAL  
• NAG 
• KIM -[ADDRESS_907384] 
• Creatinine clearance  
• Protein  
• Albumin  
 
Phospholipi[INVESTIGATOR_805]  
• Ceramides  
• Sphingolipi[INVESTIGATOR_805]  
• Diacyglycerol  
[ADDRESS_907385] ed, handled and stored under the conditions specified for the assay s. Please refer to 
the study Laboratory Manual for details on the appropriate handling and storage methods for biomarker and 
other samples . 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
87  
 
 
  
 
 
Appendix C  PK Sampling Schedule  
Sampling Schedule for Weekly Dosing Cohort  
Sampling Schedule for Every 4-Week Dosing Cohorts  
 
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
88 Appendix C  PK Sampling Schedule for  Weekly Dosing Cohort 
 Treatment Period  Follow -up Period  
Study 
Week  1 1 5 9 13 17 21 26 27 4* 8* 13* 
Study 
Day 1 2 29 57 85 113 141 176 177 178 183 *Weeks from the end of 
treatment period4 
All 
Subjects Pre-dose  NA Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-
dose  NA NA Anytime  Anytime  Anytime  Anytime  
PK Sub -
group  
Only  Pre-dose, 1, 2, 4, & 8-hr
1 24-hr2 Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose, 1, 2, 4, & 8-hr
1 24-hr2 48-hr3 Anytime  Anytime  Anytime  Anytime  
1 Window of ( -) 2 hrs  
2 24-hr from previous dose of Study Drug.  Window of (+/ -) 4 hours  
3 48-hr from previous dose of Study Drug.  Window of (+/ -) [ADDRESS_907386] dose   
ISIS 703802 -CS2 CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
89 Appendix C  PK Sampling Schedule for Every 4 -Week Dosing  Cohorts  
 Treatment Period  Follow -up Period  
Study Week  1 1 5 9 13 17 21 22 23 25 4* 8* 13* 
Study Day  1 2 29 57 85 113 141 142 143 148 155 169 *Weeks from the end of 
treatment period4 
All Subjects Pre-dose  NA Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  NA NA NA NA Anytime  Anytime  Anytime  Anytime  
PK Sub -
group only  Pre-dose , 
1, 2, 4, 
and 8- hr1 24-hr2 Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose , 1, 
2, 4, and 8-hr
1 24-hr2 48-hr3 Anytime  Anytime  Anytime  Anytime  Anytime  Anytime  
1 Window of ( -) 2 hours allowed  
2 24-hr from previous dose of Study Drug.  Window of (+/ -) 4 hours allowed  
3 48-hr from previous dose of Study Drug.  Window of (+/ -) [ADDRESS_907387] abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010. 
 
 

ISIS 703802 -CS2 CONFIDENTIAL  Amendment 2  
Protocol    25 October  2018 
 
92 Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
  
 
 

ISIS 703802 CS2  CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
93 Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 
 
  
 
  
 
  
 
  
 
 

ISIS 703802 CS2  CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
94  
 
 
  
 
   
Appendix E  Additional Laboratory Tests for Patients with 
Platelet Count <100,000/mm3 
  
 
 
  
 
  
 
  
 
  
 
ISIS 703802 CS2  CONFIDENTIAL  Amendment 2  
Protocol   25 October  2018 
 
95 Appendix E  Laboratory Tests to Be Performed in the Event of a Platelet Count 
˂ 100,000/mm3* 
*Labs only need to be performed once.  Labs may be collected over multiple visits, if blood 
requirements are a concern, as per Investigator discretion 
Note:  The following labs may change as additional data is assessed, and sites will be updated 
regarding any changes.  
To Be Performed at Local Lab  
Peripheral smear (shoul d be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Folate (folic acid)  
Vitamin B12  
Fibrinogen  
von Willebrand factor  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
Helicobacter pylori (breath test)  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV 
Parvo B19  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti-PF4 assay  
Anti-ASO antibody  
 
 